

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/52, 9/12, G01N 33/50, A61K 38/45</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/35048</b>
			<b>(43) International Publication Date:</b> 13 August 1998 (13.08.98)
<b>(21) International Application Number:</b> PCT/US98/02522 <b>(22) International Filing Date:</b> 9 February 1998 (09.02.98)  <b>(30) Priority Data:</b> 08/797,522 7 February 1997 (07.02.97) US 60/046,727 16 May 1997 (16.05.97) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</b> US 08/797,522 (CIP) Filed on 7 February 1997 (07.02.97) US 60/046,727 (CIP) Filed on 16 May 1997 (16.05.97)  <b>(71) Applicant (for all designated States except US):</b> PRINCETON UNIVERSITY [US/US]; 5 New South Building, P.O. Box 36, Princeton, NJ 08544 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SHOKAT, Kevan, M. [US/US]; 40 Lake Lane, Princeton, NJ 08544 (US).  <b>(74) Agents:</b> JACKSON, David, A. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).			<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES			
<b>(57) Abstract</b>  Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them. Modified nucleotide triphosphate substrates and methods of making and using them. Methods for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Also engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes. Methods for making and using such engineered enzymes. Modified substrates and methods of making and using them. Methods for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.			

21494  
#9

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES

5 The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others, as provided for by the terms of NSF Grant No. MCB9506929 and DHHS NCI Grant No. RO1 CA70331-01.

**I. FIELD OF THE INVENTION**

10 The present invention is in the field of biotechnology. More specifically, the invention is in a field often referred to as enzyme engineering, in which through genetic alterations or other means, the amino acid sequences of enzymes of interest are changed in order to alter or improve their catalytic properties. The embodiments of the invention which are described below involve methods in the fields of genetic engineering and enzymology, and more particularly, to the design of protein kinases and other multi-substrate enzymes, including inhibitable such enzymes, and to related materials, techniques and uses.

**II. BACKGROUND OF THE INVENTION**

20 It is only logical that cell-to-cell communications in a multicellular organism must be fast, and that they must be able to allow cells to respond to one another in diverse and complex ways. Typically, the intracellular signals used are molecules called "ligands," and a given ligand can bind to a particular type of receptor on the surface of those cells that are to receive that signal. But this simple ligand binding alone is not enough to provide for the complex responses that the receiving cells may need to make. Cells therefore amplify and add complexity to this signal through complex, often cascading mechanisms leading to the rapid modulation of catalytic activities inside the cell, which in turn can produce complex, and sometimes dramatic, intracellular responses. This process as a whole, from initial ligand binding to completion of the intracellular response, is called "signal transduction."

Signal transduction is often accomplished by the activation of intracellular enzymes that can act upon other enzymes and change their catalytic activity. This may lead to increases or decreases in the activity certain metabolic pathways, or may lead to even large intracellular changes, for example, the initiation of specific patterns of gene expression. The ability of one enzyme to alter the activity of other enzymes generally indicates that the enzyme is involved in cellular signal transduction.

The most common covalent modification used in signal transduction process is phosphorylation, which results in the alteration of the activity of those enzymes which become phosphorylated. This phosphorylation is catalyzed by enzymes known as protein kinases, which are often simply referred to as "kinases."

Several key features of the kinases make them ideally suited as signaling proteins. One is that they often have overlapping target substrate specificities, which allows "cross-talk" among different signaling pathways, thus allowing for the integration of different signals (1). This is thought to be a result of the need for each kinase to phosphorylate several substrates before a response is elicited, which in turn provides for many types of diverse signaling outcomes. For example, a given kinase may in one instance transmit a growth inhibitory signal and in another instance transmit a growth promoting signal, depending on the structure of the extracellular ligand that has bound to the cell surface (2).

A second key feature is that the kinases are organized into several modular functional regions, or "domains" (3). One domain known as "SH3" is a proline-rich region of 55-70 amino acids in length, and another, known as "SH2," is a phosphotyrosine-binding region of about 100 amino acids in length. These two domains are believed to be involved in recognizing and binding to the protein substrates. The third domain, "SH1," is comprised of about 270 amino acids, and is the domain which is responsible for catalysis. It also contains the binding site for the nucleoside triphosphate which is used as energy source and phosphate donor (3). Other domains, including



myristylation and palmitoylation sites, along with SH2 and SH3, are responsible for assembling multiprotein complexes which guide the catalytic domain to the correct targets (3,22,23). Molecular recognition by the various domains has been studied using by x-ray diffraction and by using NMR methods (24-28).

5 These domains appear to have been mixed and matched through evolution to produce the large protein kinase "family." As many as 1000 kinases are thought to be encoded in the mammalian genome (4), and over 250 kinases have already been identified. The large number of kinases and the large number of phosphorylation-modulated enzymes that are known to exist inside cells allow for rapid signal amplification and multiple  
10 points of regulation.

A third key feature of the kinases is their speed. The kinetics of phosphorylation and dephosphorylation is extremely rapid in many cells (on a millisecond time scale), providing for rapid responses and short recovery times, which in turn makes repeated signal transmission possible (5).

15 These features of the kinases have apparently led them to be used in a vast array of different intracellular signal transduction mechanisms. For example, growth factors, transcription factors, hormones, cell cycle regulatory proteins, and many other classes of cellular regulators utilize tyrosine kinases in their signaling cascades (12,13). Tyrosine kinases catalytically attach a phosphate to one or more tyrosine residues on  
20 their protein substrates. The tyrosine kinases include proteins with many diverse functions including the cell cycle control element *c-abl* (14-16), epidermal growth factor receptor which contains a cytoplasmic tyrosine kinase domain (12), *c-src*, a non-receptor tyrosine kinase involved in many immune cell functions (13), and Tyk2, a cytoplasmic tyrosine kinase which is involved in phosphorylation of the p91 protein  
25 which is translocated to the nucleus upon receptor stimulation and functions as a transcription factor (17). The serine/threonine kinases make up much if not all of the remainder of the kinase family; these catalytically phosphorylate serine and threonine

residues in their protein substrates, and they have similarly diverse roles. They share homology in the 270 amino acid catalytic domain with tyrosine kinases. As such, although the discussion which follows focuses more particularly on the tyrosine kinases, that discussion is generally applicable to the serine/threonine kinases as well.

5 Unfortunately, the very features which make kinases so useful in signal transduction, and which has made them evolve to become central to almost every cellular function, also makes them extremely difficult, if not impossible, to study and understand. Their overlapping protein specificities, their structural and catalytic similarities, their large number, and their great speed make the specific identification of their *in vivo* protein  
10 substrates extremely difficult, if not impossible, using current genetic and biochemical techniques. This is today the main obstacle to deciphering the signaling cascades involved in tyrosine kinase-mediated signal transduction (4,6-8).

Efforts to dissect the involvement of specific tyrosine kinases in signal transduction cascades have been frustrated by their apparent lack of protein substrate specificity *in*  
15 *vitro* and *in vivo* (4,8). The catalytic domains of tyrosine kinases possess little or no inherent protein substrate specificity, as demonstrated by domain swapping experiments (18-23). The catalytic domain from one tyrosine kinase can be substituted into a different tyrosine kinase with little change in the protein substrate specificity of the latter (22).

20 The poor *in vitro* specificity of kinases also makes it difficult, if not impossible, to extrapolate what the *in vivo* function of given kinases might be. An isolated tyrosine kinase of interest will often phosphorylate many test protein substrates with equal efficiency (29). This apparently poor substrate specificity is also found *in vivo*; for example, many genetic approaches, such as gene knock out experiments, give no  
25 interpretable phenotype due to compensation by other cellular tyrosine kinases (30,31).

Another complication is that many tyrosine kinases have been proposed to phosphorylate downstream and upstream proteins which are themselves tyrosine kinases; although this appears to make complex positive feedback loops possible, it also makes dissecting the cascade even more difficult (1).

5 One important avenue for deciphering the role and understanding the function of enzymes, both *in vitro* and *in vivo*, is the use of specific enzyme inhibitors. If one or more compound can be found that will inhibit the enzyme, the inhibitor can be used to modulate the enzyme's activity, and the effects of that decrease can be observed. Such approaches have been instrumental in deciphering many of the pathways of  
10 intermediary metabolism, and have also been important in learning about enzyme kinetics and determining catalytic mechanisms.

In addition, such inhibitors are among the most important pharmaceutical compounds known. For example, aspirin (acetylsalicylic acid) is such an inhibitor. It inhibits an enzyme that catalyzes the first step in prostaglandin synthesis, thus inhibiting the  
15 formation of prostaglandins, which are involved in producing pain (72). Traditional drug discovery can be characterized as the design and modification of compounds designed specifically to bind to and inactivate a disease-causing protein; the relative success of such an effort depends upon the selectivity of the drug for the target protein and its lack of inhibition of non-disease associated enzymes with similar enzyme  
20 activities.

Such approaches would appear to be promising ways to develop treatments for cancer, since many human cancers are caused by dysregulation of a normal protein (e.g., when a proto-oncogene is converted to an oncogene through a gene translocation). And since kinases are key regulators, they have turned out to be very common proto-  
25 oncogenes, and thus ideal drug design targets.

The process of designing selective inhibitors is relatively simple in cases where few

similar enzymes are present in the target organism, for example in cases where inhibitors of a protein unique to bacteria can be targeted. But unfortunately, the similarities between the kinases and their large number has almost completely frustrated the discovery and design of specific inhibitors, and has blocked most hopes of developing specific pharmaceutical treatments aimed at the proto-oncogene level. It is expected that the vast majority of candidate inhibitors will inhibit multiple kinases, even though they may have initially been identified as inhibiting a particular, purified kinase.

This is not to say, however, that inhibitors with at least some degree of kinase-specificity cannot be found. Several natural products have been identified which are relatively specific for particular kinase families, but attempts to derive general rules about kinase inhibition based on these has failed. Furthermore, as the following examples show, specificity in most cases is quite limited. For example, the compound Damnacanthal was reported to be a "highly potent, selective inhibitor" of the kinase p56lck (73); as shown in Fig. 2A, this compound has an inhibition constant ( $IC_{50}$ ) for that kinase which is almost seven times lower than for the kinase *src* (the  $IC_{50}$  is the concentration of inhibitor which must be added to reduce catalytic activity by 50%). The compound PPI (Fig. 2B) has a binding affinity for the kinase *lck* which is very strong ( $IC_{50} = 0.005 \mu M$ ); but unfortunately, the inhibition of other kinases of the *src* family is very similar. It inhibits the kinase *fyn* with an almost identical  $IC_{50}$ ,  $0.006 \mu M$ , and has only about a 4-fold higher  $IC_{50}$  for the kinase *hck* ( $IC_{50} = 0.020 \mu M$ ). The compound CGP 57148 (Fig. 2C) has been reported to be "semi-selective" for the kinases *abl* ( $IC_{50} = 0.025 \mu M$ ) and PDGFR ( $IC_{50} = 0.030 \mu M$ )(74). Nevertheless, considering the vast number of kinases and their relative cellular importance, and also considering that the above-described inhibitors have only been reported in the last two years, it appears that success in discovering or designing selective kinase inhibitors has been remarkably limited.

These difficulties described above have implications well beyond the mere frustration

of scientists; they have frustrated efforts to decipher the kinase cascades and the function of individual kinases in those cascades and other cellular mechanisms. Such an understanding of kinase activity and function may be essential before certain human diseases can be effectively treated, prevented or cured. For example, it has been known for over 30 years that the oncogene *bcr-abl* is a protein kinase that is responsible for chronic myelogenous leukemia; but the physiological substrates that it acts upon to cause oncogenesis, which may be important drug design targets, have yet to be definitively identified (11). On the bright side, despite this shortcoming, the above-described inhibitor CGP 57148 is reportedly now undergoing clinical trials for use in treating myelogenous leukemia, even though the substrates it may block phosphorylation of *in vivo* are not known.

The medical significance of these difficulties is further illustrated by the Rous sarcoma virus (RSV), which has become an important model system for studying the role of kinases in oncogenesis. RSV transformation of fibroblasts is controlled by a single viral gene product, the protein tyrosine kinase *v-src* (32). It is the rapid time course and the dramatic morphological changes during RSV fibroblast transformation that have made RSV a paradigm for studies of oncogene activity in all cells. The origin (33), regulation (3,8,34,35), and structure (25,27,36) of *v-Src* have been extensively studied and are well understood (8,37,38). But central questions about this intensely studied kinase remains unanswered: what are its *direct* cellular substrates? Does inhibition of its catalytic activity effectively inhibit, or even reverse, transformation? Would such inhibition be an effective therapy for or prophylactic against RSV transformation? Unfortunately, as discussed above, the answers to these questions are not forthcoming, largely because the number of cellular kinases is enormous (it is estimated that 2% of the mammalian genome encodes protein kinases (4)) and because tyrosine kinases display overlapping substrate specificities (8,39) and share catalytic domains, making the design of specific inhibitors enormously difficult.

The expression of *v-Src* in fibroblasts results in the tyrosine phosphorylation of over

50 cellular proteins (37). These same substrates are also phosphorylated by other kinases in untransformed fibroblasts (40). Even the most sophisticated biochemical and genetic techniques, including anti-phosphotyrosine protein blots of transformed fibroblasts, transfection of fibroblasts with transformation-defective v-Src mutants, temperature-sensitive v-Src mutants, gene knock-out studies of cellular Src, host-range dependent Src mutants, anti-v-Src immunoprecipitation, and use of kinase-specific inhibitors, have not led to the unambiguous identification of v-Src's direct substrates (see reference (38) for a comprehensive review). But this situation is not unique; in fact, the direct substrates for the majority of cellular kinases remain unidentified (8). Furthermore, as discussed above, there also are remarkably few compounds known to selectively inhibit individual kinases, or even groups of related kinases.

Although the forgoing difficulties are daunting, new methods of rational drug design and combinatorial organic synthesis make the design or discovery of kinase-specific inhibitors feasible given sufficient resources. However, because the kinase networks are highly degenerate and interconnected in unknown ways, there is considerable uncertainty with regard to many diseases which kinases should be targeted for inhibition. Moreover, it is by no means clear that a specific inhibitor of a given kinase will have any effect on the disease, either *in vitro* or *in vivo*. Because kinases can be highly promiscuous, there is a significant chance that inhibiting one kinase will simply force another kinase to "take its place." Therefore, there is a need for a simple and direct way to determine the biochemical and cellular effects of inhibiting a given kinase, before herculean efforts are undertaken to design or discover specific inhibitors.

From the forgoing, it is clear that there has been a long felt but unsatisfied need for ways to identify which cellular proteins are acted upon by individual protein kinases. Such a method would ideally also allow for the quantitative measurement of relative activity of a given kinase on its protein substrates, which could be used, for example,

to detect how or whether actual or potential drug compounds might modulate kinase activity. In addition, there has also been a need for specific inhibitors of individual kinases or kinase families, which could be used to identify protein substrates (by looking for which proteins are not phosphorylated or are more weakly

5 phosphorylated in the presence of the inhibitor), to study the biochemical and phenotypic effects of rapidly down-regulating a given kinase's activity, for use as drugs to treat kinase-mediated diseases, and to confirm that tedious efforts to design or develop more traditional inhibitor drugs would be worthwhile.

10 As is described in considerable detail below, the present invention for the first time provides a method for the highly specific inhibition of individual kinases, which have been engineered to bind the inhibitor more readily than the wild-type form of that kinase or other, non-engineered kinases. The invention also provides for the engineered kinases and the inhibitors to which they are adapted.

15 Moreover, as will become apparent, this method is even more broadly applicable, as it would provide similar advantages for the study of other enzymes which, like the kinases, covalently attach part of at least one substrate to at least one other substrate.

20 The present invention involves the engineering of kinases and other multi-substrate enzymes such that they can become bound by inhibitors which are not as readily bound by their wild-type forms. Modified substrates and mutant enzymes that can bind them have been used to study an elongation factor (41) and a receptor for cyclophilin A (42). However, prior to the present invention, it was not known how, or even if, multi-substrates enzymes which covalently attach part or all of a donor substrate onto a recipient substrate could be engineered to bind to an inhibitor, yet still retain at least some catalytic activity and at least some specificity for the recipient

25 substrate in the absence of the inhibitor. The present invention is that this can be done, as explained below; and this invention for the first time opens the door to the selective inhibition of individual kinases, which are not only important tools for understanding of the kinase cascades and other complex catalytic cellular

mechanisms, but also may provide avenues for therapeutic intervention in diseases where those mechanisms come into play.

### III. SUMMARY OF THE INVENTION

The present invention provides a solution to the above-described problems by providing materials and methods by which a single protein kinase can be specifically inhibited, without the simultaneous inhibition of other protein kinases.

In a first aspect, the present invention involves the engineering of kinases and other multi-substrate enzymes such that they can utilize modified substrates which are not as readily used by their wild-type forms. The invention further provides such chemically modified nucleotide triphosphate substrates, methods of making them, and methods of using them. The methods of the present invention include methods for using the modified substrates along with the engineered kinases to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action.

In a further aspect, the invention provides engineered protein kinases which can bind inhibitors that are not as readily bound by the wild-type forms of those enzymes. Methods of making and using all such engineered kinases are also provided. The invention further provides such inhibitors, methods of making them, and methods of using them. The methods of the present invention include methods for using the inhibitors along with the engineered kinases to identify which protein substrates the kinases act upon, to measure the kinetics of such action, and to determine the biochemical and cellular effects of such inhibition. They also relate to the use of such inhibitors and engineered kinases to elucidate which kinases may be involved in disease; these kinases can then become the subject of efforts to design or discover more traditional specific inhibitors of their wild-type forms, which may prove to be valuable in treating the kinase-related disease or disorder.



Furthermore, methods are provided for inserting the engineered kinase into cells or whole animals, preferably in place of the corresponding wild-type kinase, and then using the inhibitor to which it has been adapted as a tool for study of the disease-kinase relationship, and ultimately, as a drug for the treatment of the disease.

5       The present invention also more generally relates to engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate. These engineered forms will accept modified substrates and inhibitors that are not as readily bound by the wild-type forms of those enzymes.

10       The invention also relates to methods for making and using such engineered enzymes, as well as the modified donor substrates. The methods of the present invention include methods for using the modified substrates and inhibitors along with the engineered enzymes to identify which substrates the enzymes act upon, to measure the kinetics of such action, and in the instance of the modified substrates, to determine the  
15       recipient substrates to which part or all of the donor substrate becomes attached, to measure the extent of such action, and to identify and measure the extent of modulation thereof by test compounds.

In the instance of inhibitors, the methods seek to determine the biochemical and cellular effects of such inhibition. The methods also extend to the use of such  
20       inhibitors and engineered enzymes to elucidate which enzymes may be involved in disease; these enzymes can then become the subject of efforts to design or discover specific inhibitors of their wild-type forms, which may prove to be valuable in treating the enzyme-related disease or disorder. Furthermore, methods are provided for inserting the engineered enzyme into cells or whole animals, preferably in place of the  
25       corresponding wild-type enzyme, and then using the inhibitor to which it has been adapted as a tool for study of the disease-enzyme relationship, and ultimately, as a drug for the treatment of the disease.

According to the present invention, through enzyme engineering a structural distinction can be made between the nucleotide binding site of a protein kinase of interest, and the nucleotide binding sites of other kinases. This distinction allows the engineered kinase to use a nucleotide triphosphate or an inhibitor that is not as readily bound by the wild-type form of that kinase, or by other kinases. In a preferred embodiment with respect to the inhibitor, the inhibitor used is one that is "orthogonal" to the "natural" nucleotide triphosphate substrate for that kinase, or is orthogonal to a less specific inhibitor (e.g., one which is readily bound by the wild-type form of that kinase). The term "orthogonal," as further discussed below, means that the substrate or inhibitor is similar in structure (including those that are geometrically similar but not chemically similar, as described below), but differs in a way that limits its ability to bind to the wild-type form.

An engineered kinase made according to the present invention will be able to use an orthogonal nucleotide triphosphate substrate that is not as readily used by other, non-engineered kinases present in cells. Preferably, it will be able to use an orthogonal nucleotide triphosphate that is not substantially used by other kinases; and most preferably, it will be able to use an orthogonal nucleotide triphosphate substrate that can not be used at all by other kinases. By labeling the phosphate on the orthogonal substrate, e.g., by using radioactive phosphorous ( $P^{32}$ ), and then adding that labeled substrate to permeabilized cells or cell extracts, the protein substrates of the engineered kinase will become labeled, whereas the protein substrates of other kinases will be at least labeled to a lesser degree; preferably, the protein substrates of the other kinases will not be substantially labeled, and most preferably, they will not be labeled at all.

The detailed description and examples provided below describe the use of this strategy to uniquely tag the direct substrates of the prototypical tyrosine kinase, v-Src. Through protein engineering a chemical difference has been made in the amino acid sequence which imparts a new structural distinction between the nucleotide binding

site of the modified v-Src and that of all other kinases. The v-Src kinase we have engineered recognizes an ATP analog (A\*TP), N<sup>6</sup>-(cyclopentyl)ATP, which is orthogonal to the nucleotide substrate of wild-type kinases. The generation of a v-Src mutant with specificity for an orthogonal A\*TP substrate allows for the direct substrates of v-Src to be uniquely radiolabeled using [ $\gamma$ -<sup>32</sup>P] N<sup>6</sup>-(cyclopentyl)ATP, because it is able to serve as substrate to the engineered v-Src kinase, but is not substantially able to serve as substrate for other cellular kinases.

The detailed description and examples provided below describe the use of this strategy to uniquely identify the direct substrates of the prototypical tyrosine kinase, v-Src. Through protein engineering a chemical difference has been made in the amino acid sequence which imparts a new structural distinction between the nucleotide binding site of the modified v-Src and that of all other kinases. The engineered v-Src kinases that have been made and presented herein bind to an orthogonal analog of the more general kinase inhibitor PP3: the compound N04 cyclopentoyl PP3. The generation of a v-Src mutant with specificity for such an inhibitor allows for the mutant to be inhibited, whereas other kinases in the same test system are not substantially inhibited, not even the wild-type form of that same kinase.

As is apparent from the forgoing, it is one object of the present invention to provide a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate.

Another object of the present invention to provide a nucleotide sequence which encodes such a mutant protein kinase; and it is a further object to provide a method for producing such a nucleic acid sequence.

It is also an object of the invention to provide methods for producing such a mutant protein kinase, for example, by expressing such a nucleic acid sequence.

It is also an object of the present invention to provide such orthogonal nucleotide triphosphates and methods for their synthesis, including N<sup>6</sup>-(cyclopentyl)ATP, N<sup>6</sup>-(cyclopentyloxy)ATP, N<sup>6</sup>-(cyclohexyl)ATP, N<sup>6</sup>-(cyclohexyloxy)ATP, N<sup>6</sup>-(benzyl)ATP, N<sup>6</sup>-(benzyloxy)ATP, N<sup>6</sup>-(pyrolidino)ATP, and N<sup>6</sup>-(piperidino)ATP (27).

It is yet another object of the invention to provide a method for determining whether a test compound positively or negatively modulates the activity of a protein kinase with respect to one or more protein substrates.

More particularly, and in accordance with the further aspect of the invention, it is a primary object provide a mutant protein kinase which binds to and is inhibited by an inhibitor, which inhibitor less readily binds to or inhibits the corresponding wild-type kinase.

A further object of the present invention is to provide a nucleotide sequence which encodes such a mutant protein kinase; and it is a further object to provide a method for producing such a nucleic acid sequence.

It is also an object of the invention to provide methods for producing such a mutant protein kinase, for example, by expressing such a nucleic acid sequence.

It is another object of the present invention to provide such inhibitors, such as the compound N-4 cyclopentoyl PP3, and methods for their synthesis.

Another object is to provide a method for determining what are the substrates for a given protein kinase.

It is yet another object of the invention to provide a method for determining whether specific inhibition of a particular kinase produces a biochemical or phenotypic effect

in a test systems such as a cell-free extracts, cell cultures, or living multicellular organisms.

It is a further object of the invention to provide a method to determine whether inhibition of a particular kinase might have therapeutic value in treating disease.

5 It is yet another object to provide methods for the study of the activity, kinetics, and catalytic mechanisms of a kinase by studying the inhibition of the corresponding mutant of the present invention.

10 A further object is to provide a methods of preventing and treating kinase-mediated diseases by introducing an inhibitor-adapted mutant kinase of the present invention into a diseased organism, and preferably diminishing or, most preferably, depleting the organism of the wild-type enzyme; and then administering the inhibitor to regulate the activity of the now disease-mediating mutant kinase so as to diminish or eliminate the cause or symptoms of the disease.

15 Based upon the forgoing and the detailed description of the present invention provided below, one of ordinary skill in the art will readily recognize that the present invention can be used more generally to study multi-substrate enzymes which covalently transfer a donor substrate or portion thereof to a recipient substrate, as do the kinases. Such applications of the present invention are also further described in the detailed description which follows.

20 Accordingly, it is yet a further object of the present invention to provide a mutant multi-substrate enzyme which binds to an inhibitor, which inhibitor is less readily bound to the wild-type enzyme or to other enzymes with similar activity.

It is another object of the invention to provide a nucleotide sequence which encodes such a mutant multi-substrate enzyme; and it is a further object to provide a method

for producing such a nucleic acid sequence.

It is also an object of the invention to provide methods for producing such a mutant multi-substrate enzyme, for example, by expressing such a nucleic acid sequence.

It is also an object of the present invention to provide such inhibitors and methods for their synthesis.

Another object is to provide a method for determining what are the substrates for a given multi-substrate enzyme.

It is yet another object of the invention to provide a method for determining whether specific inhibition of a particular multi-substrate enzyme produces a biochemical or phenotypic effect in a test systems such as a cell-free extracts, cell cultures, or living multicellular organisms.

It is a further object of the invention to provide a method to determine whether inhibition of a particular multi-substrate enzyme might have therapeutic value in treating disease.

It is yet another object to provide methods for the study of the activity, kinetics, and catalytic mechanisms of a multi-substrate enzyme by studying the inhibition of the corresponding mutant of the present invention.

A further object is to provide a methods of preventing and treating multi-substrate enzyme-mediated diseases by introducing an inhibitor-adapted multi-substrate enzyme of the present invention into a diseased organism, and preferably diminishing or, most preferably, depleting the organism of the wild-type enzyme; and then administering the inhibitor to regulate the now disease-mediating mutant enzyme so as to diminish or eliminate the cause or symptoms of the disease.

These and other objects of the present invention will, from the detailed description, examples and claims set forth below, become apparent to those of ordinary skill in the art.

#### IV. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic representation of the protein domain structures of v-Src, of XD4 (which has a deletion of residues 77-225), of the glutathione S-transferase (GST)-XD4 fusion protein, and of the GST-XD4 fusion protein double mutant (V323A, I338A);

FIG. 2 is a schematic representation of adenosine triphosphate (ATP), with an "X" bound to the N<sup>6</sup> position; and in the box below, schematic representations are provided for the twelve side chains that take the place of "X" in each of the orthogonal ATP analogs described in the examples (which are always referred to by the numbers 1-12 set forth in bold typeface);

FIG. 3 is an anti-phosphotyrosine immunoblot showing the level of protein tyrosine phosphorylation following treatment of a murine lymphocyte cell lysate with ATP or one of the ATP analogs (A\*TPs);

FIG. 4 provides a close-up view of the X-ray model showing the ATP binding domain in cAMP dependent protein kinase (1ATP);

FIG. 5 shows (a) an anti-phosphotyrosine blot of cell lysates expressing XD4 and GST-XD4(V323A, I338A), (b) an autoradiogram showing levels of phosphorylation when cell lysates are provided only radiolabeled ATP or only radiolabeled N<sup>6</sup>(cyclopentyl)ATP, and © an autoradiogram showing autophosphorylation of GST-XD4 and GST-XD4(V323A, I338A) by radiolabeled ATP and radiolabeled N<sup>6</sup>(cyclopentyl)ATP(A\*TP(8));

FIG. 6 is a bar chart showing the relative degree to which ATP and each of the twelve

ATP analogs inhibits GST-XD4 and GST-XD4(V323A, I338A) catalyzed phosphorylation by radiolabeled ATP;

FIG. 7 shows autoradiograms indicating the levels of autophosphorylation by several v-Src position 338 single mutants when provided with either radiolabeled ATP and radiolabeled N<sup>6</sup>(cyclopentyl)ATP as phosphate donor substrate;

FIG. 8 is a schematic diagram of a method of the present invention for determining which phosphorylated substrates in cells were phosphorylated by a particular kinase, here v-src.

FIG. 9 is a schematic diagram of how an engineered kinase of the present invention can be inhibited by an inhibitor of the present invention, even in the presence of other kinases, and can be used to reveal the kinase's protein substrates;

FIG. 10 shows the chemical structures for three known kinase inhibitors, Damnacanthal, PPI and CGP 57148, along with summaries of their inhibition constants (IC<sub>50</sub>) for several kinases;

FIG. 11A shows the core structure of adenosine and PP3, and

FIG. 11B shows the structures of several bulky substituents which can be added to N4 nitrogen of PP3 to produce the inhibitor candidate compounds whose IC<sub>50</sub> values are listed in Table 1;

FIG. 12 shows the chemical structure of N-4 cyclopentoyl PP3, and autogradiograms of electrophoresed proteins which have become radiolabeled in the presence of N-4 cyclopentoyl PP3 in the presence of either wild-type v-Src or the mutant (I338G);

FIG. 13A-C is a chart presenting additional inhibitor analogs prepared and tested in



accordance with the present invention;

FIG. 14A.) Schematic representation of the specificity problems associated with using small molecule protein kinase inhibitors to deconvolute cell signaling. Kinase catalytic domains (red ovals) are highly conserved. Thus, the majority of potent inhibitors block the activity of closely related kinases and broadly down regulate pathways mediated by kinase activity. b.) Schematic representation of the approach toward selective protein kinase inhibition described here. A space creating mutation is introduced into the ATP binding site of the kinase of choice (Src). This mutation creates an active site pocket (notch) in Src which can be uniquely recognized by a rationally designed small molecule inhibitor. This inhibitor contains a bulky chemical group (bump) which makes it orthogonal to wild type protein kinases. Design of the complementary kinase/inhibitor pair allows for highly selective inhibition of the target kinase in the context of a whole cell.

FIG. 15A.) Structure of N-6 cyclopentyloxyadenosine (1). b.) Synthesis of pyrazolo[3,4-*d*]pyrimidine inhibitor analogues. 2 was synthesized according to Hanefeld, *et al.* . (i)  $\text{RCOCl}$  (10 equiv.), pyridine, 5(C, 1h; then warm to 22(C, 11h; (ii)  $\text{LiAlH}_4$  (3.0 equiv), dry THF under argon, 0(C, 30 min; then heat to reflux for 30 min. All compounds were characterized by  $^1\text{H}$  NMR (300MHz) and high resolution mass spectrometry (EI).

FIG. 16a.) Chemical structures of quercetin (5) and AMP PNP (6). b.) Predicted binding orientation of 2 in src family kinase active sites. The crystal structures of Hck bound to AMP PNP (red) and Hck bound to quercetin (blue) were superimposed according to the Hck protein backbone (white) . The structure of 2 (yellow) was subsequently docked into the kinase active site by superimposing the pyrazolo[3,4-*d*]pyrimidine ring system of 2 onto the adenine ring of AMP PNP. c.) Predicted close contact between N-4 of 2 and the side chain of residue 338 in src family kinases. Molecule 2 has been docked into the ATP binding site of the src

family kinase, Hck, as in Fig. 3b. The atoms of the threonine 338 side chain and **2** are colored according to their elemental makeup (green=carbon, blue=nitrogen, red=oxygen, white=hydrogen) and the Hck backbone is shown in purple. The methyl hydrogens of the threonine side chain are not shown. Images were generated using the program InsightII.

FIG. 17 Inhibitor analogue **3g** does not inhibit B cell receptor mediated tyrosine phosphorylation. Murine spleen cells were incubated with 1.1% DMSO (lanes 1-2), 100 mM **3g** in 1.1% DMSO (lane 3), or 100 mM **2** in 1.1% DMSO (lane 4). B cell stimulation (lanes 2-4) was initiated by the addition of 10mg/mL goat anti-mouse IgM. Cellular proteins were resolved by 10% PAGE, transferred to nitrocellulose, and immunoblotted with a monoclonal antibody for phosphotyrosine (4G10).

FIG. 18 Inhibitor **3g** blocks p36 phosphorylation in I338G v-Src, but not WT v-Src transformed NIH3T3 fibroblasts. Non-transformed NIH3T3 cells (lane 1), WT v-Src transformed NIH3T3 cells (lanes 2-3), and I338G v-Src transformed NIH3T3 cells (lanes 4-5) were incubated with 1.1% DMSO (lanes 1, 2 and 4) or 100 mM **3g** in 1.1% DMSO (lanes 3 and 5). After 12 hours, the cells were lysed. Phosphorylation levels were determined as in Fig. 4.

FIG. 19 I338G v-Src transformed fibroblasts selectively acquire a flattened morphology and selectively regain actin stress fibers upon incubation with **3g**. Non-transformed (a.-b.), WT v-Src transformed (c., d., g., h.), and I338G v-Src transformed (e., f., i., j.) NIH3T3 fibroblasts were treated with either 1.1% DMSO (a.-c., e., g., i.) or 100 mM **3g** in 1.1% DMSO (d., f., h., j.). After 48 hours cells were photographed (a., c.-f.), stained with phalloidin-FITC, and visualized (b., g.-j.) by fluorescence microscopy..

## V. DETAILED DESCRIPTION OF THE INVENTION

**Figure 9**

This figure shows a schematic representation of an experiment to Identify Kinase Substrates below which uses the invention for discovery of the substrates of a Src protein kinase. The ovals at the top of the figure represent protein kinase substrates which become phosphorylated by the protein kinases adjacent to the arrow. The protein kinases containing several ovals connected by lines are members of the "Src-Family" of protein kinases (Src, Fyn, Lck). One kinase (Src) contains a notch cut out which represents the I338G mutation which creates an extra space in the adenine binding pocket of this kinase. The symbol above this kinase represents the orthogonal inhibitor which contains a protrusion which complements the mutation in the Src I338G kinase, resulting in its unique inhibition. The kinase with a large round oval and two protruding stings is the F-Actin Dependent protein kinase (FAK). The protein kinases with only an oval are members of the serine or threonine specific protein kinase family. The ovals below the arrow containing small P's represent the phosphorylated (P) substrates after action by the protein kinases. The simulated gels at the bottom of the figure represent the expected results if cells expressing either all wild-type kinases (on left) or one mutant kinase (Src-I338G) in place of wild-type Src are treated with the orthogonal inhibitor. The inhibitor should have no effect on the phosphoproteins present in the cells which do not express the mutant Src kinase (identical pattern in the gel on the left) and several phosphoproteins should be absent following treatment of the mutant expressing cells with the inhibitor (gel on the right).

**The Inhibitors**

Figs. 11A and 11B show the structures of a variety of bulky substituents which, when added to either N-4 of PP3 or to N<sup>6</sup> of adenosine diphosphate, or to N<sup>6</sup> of adenosine monophosphate, or to N<sup>6</sup> of adenosine (specifically N<sup>6</sup> cyclopentyloxy adenosine) to produce inhibitors of the mutant kinase v-Src(T120G), which is an engineered kinase of the present invention; the synthesis and inhibition constants for these inhibitors are discussed in Example 12 below.

Such inhibitors may be useful in studies directed towards developing other useful mutants of this and other kinases, and for the several methods described elsewhere herein. However, the scope of the present invention is not limited to the use of these particular inhibitors, and those of ordinary skill in the art will recognize that many other possible structures could be substituted for or supplement those described herein.

For example, different, simpler, and even more complex aliphatic or aromatic groups could be added to the N<sup>6</sup> position of ADP or to the N<sub>4</sub> position of PP3. In addition, the inhibitors of the present invention are not limited to modifications of nucleotides at the N<sup>6</sup> position or modifications of PP3 at the N<sub>4</sub> position. Chemical means to modify various positions on such compounds are known, and any of the resulting derivatives would be within the scope of the present invention; it is even possible to make changes or substitutions in their ring structures. Exemplary variants are presented herein, and particular reference is made to Fig. 13 where both analogs and data relating to their activity is set forth. Of course, the use of such inhibitors may require that different positions in the protein sequence of the kinase be modified in order to make an engineered kinase that will bind to them, but such different modifications are well within the scope of the present invention.

In addition, it is important to note that the inhibitors of the present invention are not limited to ADP and PP3 derivatives. For example, it should be possible to utilize derivatives of other natural nucleotide phosphate donor substrate as such inhibitors. For studying some kinases, different analog bases may in fact be preferred. For example, it is known that some kinases utilize GTP as phosphate donor substrate and energy source; to make inhibitors for engineered forms of such kinases, analogs of guanosine diphosphate would be suitable. Furthermore, it is well known that related compounds (*e.g.*, other bases) and compounds chemically unrelated to the natural substrate can sometimes nevertheless bind to an active site, and can (but for the purposes of this invention need not), be acted upon or act upon other substrates

through chemical catalysis by the enzyme. Sometimes they participate in the catalyzed reaction in the same way as the natural substrate, sometimes in different ways. Such compounds and their derivatives would be suitable starting points for the design of inhibitors that are orthogonal to them, and which would be within the scope of the present invention. Similarly, other known kinase inhibitors can be used as a starting point for synthesis of inhibitors of the present invention, such as those whose structures appear in Fig. 10. Of course, even derivatives of inhibitors that are currently unknown would, once identified, be suitable core structures for the design of inhibitors of the present invention, as illustrated herein and made a part hereof.

Furthermore, the inhibitors of the present invention are not limited to those made by chemical synthetic means, but also include compounds which may be found in nature, and which can serve that role, some of which are discussed above. In addition, those of ordinary skill in the art will appreciate that there are other variations besides those set forth here, and that these are all within the scope of the present invention.

The inhibitors that are candidates for use in accordance with the present invention can conveniently be screened to determine the extent to which they are accepted by wild-type kinases, using a screening procedure such as that set forth in Example 13 below, or by a screening procedure involving the use of a cell or cells which are rich in protein kinase activity as set forth in Example 9 herein. By such an assay, one can determine whether each inhibitor is bound by wild-type kinases to a lesser degree than the engineered kinases, or preferably, if the wild-type kinases do not substantially bind to that inhibitor, or most preferably, do not bind the inhibitor at all. For those substrates that are least less readily bound, it may be worthwhile to try to engineer the kinase of interest so that it will more readily bind to them. Of course, one could make the engineered kinase first and then assay it along side the wild-type enzyme to determine whether it uses a given orthogonal substrate better than the wild-type kinase; this was the approach used in Example 13. However, under most circumstances, pre-screening as described above will be preferred. Of course, other

assay approaches will be apparent to those in the field, and the use of such assays would be within the scope of the present invention.

### **The Engineered Kinases**

There are several criteria that should be satisfied in reengineering a kinase in order to uniquely tag its *authentic* substrates in the presence of wild type tyrosine and serine/threonine kinases. The engineered kinase should: (1) accept an ATP analog (A\*TP) that is utilized less readily by wild-type protein kinases; preferably, accept an A\*TP that is not substantially utilized by wild-type kinases; and most preferably, accept an A\*TP that is not utilized by wild-type kinases at all; (2) preferably, use the A\*TP analog with high catalytic efficiency; and (3) preferably, have reduced catalytic efficiency for the natural nucleotide substrate (ATP) so that in the presence of cellular levels of ATP (1-2 mM) the mutated kinase would preferentially utilize A\*TP as the phosphodonor. If such engineered kinases are to be used to study the protein substrate specificity of the wild-type kinase, then these criteria must be met without substantially altering the protein target specificity of the kinase.

Likewise several criteria should be satisfied in reengineering a kinase in order that it will be inhibited by the inhibitors of the present invention. The engineered kinase should: (1) bind to an inhibitor which is bound less readily by wild-type protein kinases; preferably, the inhibitor will not substantially bind to wild-type kinases; and most preferably, will not bind at all to wild type kinases; (2) preferably, the engineered kinase will bind the inhibitor with high affinity (i.e., low  $IC_{50}$ ). It is not generally of particular importance whether the inhibitor binds to the wild-type form of the kinase that corresponds to the engineered kinase, as such binding and the resulting inhibition would augment that of the engineered kinase. However, it is most likely that the wild-type form of that kinase will not bind the inhibitor any better than other wild-type kinases. If an inhibitable engineered kinase is to be used to study the protein substrate specificity of the wild-type kinase, or to replace the wild-type form of that kinase through gene therapy or other means, as further discussed below, then a

further concern is that the above-described criteria must preferably be met without substantially altering the protein target specificity of the engineered kinase when compared with the corresponding wild-type form.

When viewed from the perspective of the state of the art when the present invention was made, it was not predictable whether it would be possible to satisfy all of these criteria simultaneously; in fact, it was doubtful, because the ATP binding site that is engineered is very close to the second substrate binding site, *i.e.*, the peptide binding site. However, as shown by the examples below, all of these criteria, including the preferred criteria, were in fact met simultaneously when we made the described v-Src mutants, provided them with N<sup>6</sup>(cyclopentyl)ATP and inhibited them using N4-cyclopentyl PP3.

Example 1 describes the twelve ATP analogs which were used in the studies on mutant v-Src, which are described in the further examples which follow. These orthogonal ATP analogs may be useful in studies directed towards developing other useful mutants of this and other kinases, and for the several methods described elsewhere herein. However, the scope of the present invention is not limited to the use of these particular ATP analogs, and those of ordinary skill in the art will recognize that many other possible orthogonal substrates could be substituted for or supplement those described herein. For example, different and even more complex aliphatic or aromatic groups could be added to the N<sup>6</sup> position of ATP. In addition, the orthogonal substrates of the present invention are not limited to modifications of nucleotides at the N<sup>6</sup> position. Chemical means to modify various positions on adenosine are known, and any of these would be within the scope of the present invention; and it is even possible to make changes or substitutions in the ring structures of nucleotides. Of course, the use of such orthogonal substrates may require that different positions in the protein sequence of the kinase be modified in order to make an engineered kinase that will bind to them, but such different modifications are well within the scope of the present invention.

In addition, it is important to note that the orthogonal substrates of the present invention are not limited to ATP derivatives. For studying different kinases, different analog bases may in fact be preferred. For example, it is known that some kinases utilize GTP as phosphate donor substrate and energy source; for studies of such kinases, analogs of guanosine triphosphate would be preferred. It is well known that compounds chemically unrelated to the natural substrate can sometimes nevertheless bind to an active site, and can even be acted upon or act upon other substrates through chemical catalysis by the enzyme. Sometimes they participate in the catalyzed reaction in the same way as the natural substrate, sometimes in different ways. Such compounds and their derivatives would also be within the scope of the terms "natural substrate" and "orthogonal substrate" as used herein.

Furthermore, the orthogonal substrates of the present invention are not limited to those made by chemical synthetic means, but also include compounds which may be found in nature, and which can serve that role. Those of ordinary skill in the art will appreciate that there are other variations besides those set forth here, and that these are all within the scope of the present invention.

The orthogonal nucleotides that are candidates for use in accordance with the present invention can conveniently be screened to determine the extent to which they are accepted by wild-type kinases, using a screening procedure such as that set forth in Example 2 below. By such an assay, one can determine whether each orthogonal substrate is accepted by wild-type kinases to a lesser degree than the normal substrate for such kinases, or preferably, do not substantially accept that substrate, or most preferably, do not accept it at all. For those substrates that are least less readily accepted, it may be worthwhile to try to engineer the kinase of interest so that it will more readily accept them. Of course, one could make the engineered kinase first and then assay it along side the wild-type enzyme to determine whether it uses a given orthogonal substrate better than the wild-type kinase. However, under most circumstances, pre-screening such as is described in Example 2 will be preferred. Of



course, other assay approaches will be apparent to those in the field, and the use of such assays would be within the scope of the present invention.

The design of an engineered v-Src is described in Example 3 below. As is described, the engineered form was designed by reference to the crystal structures of other kinases which have domains that are homologous to those found in most if not all kinases. As will be seen, the example mutant kinases described herein have been constructed as fragments of protein kinases, rather than as containing the entire sequences; but it was found there is no substantial difference in performance when the entire sequence is used. Of course, the concepts and the practicalities are the same whether fragments or whole kinases are used, and both are within the scope of the present invention. As such, the term "kinase" should be viewed as including the whole enzyme or a fragment of one, including when interpreting the claims.

Using this approach, it is possible to design similar mutants of virtually any other kinase. The method for doing this comprises the steps of: (a) identifying, from the crystal structure of an identical or homologous enzyme bound to its phosphate donor substrate or to a known kinase inhibitor (which may be non-specific for kinases, specific for kinases generally but not for that kinase, or specific for that kinase), one or more amino acids other than glycine which are close enough to a substituent on the bound phosphate donor substrate or inhibitor that they would sterically restrict entry of a bulky substituent attached to that substituent in a putative orthogonal inhibitor; and (b) mutating a nucleotide sequence which encodes the wild-type protein kinase such that the nucleotide triplets encoding one or more of the identified amino acids, are converted to nucleotide triplets that encode amino acids having side chains that are sterically less bulky than the identified amino acids.

The above-described method uses steric restriction of entry or exclusion as the criteria for deciding which amino acid(s) to change, and how to change them. However, the present invention is not so limited. It is also possible to engineer a kinase to change

its ability to bind to an orthogonal substrate by considering other factors, such as hydrophobicity, hydrophilicity, ionic binding or repulsion, hydrogen bonding, forming covalent bonds between the enzyme and electrophilic groups on orthogonal substrates, etc.

5 The study of protein kinases using the present invention will be greatly facilitated by the vast knowledge regarding the domain structure of many different kinases, and their generally homologous sequences. The Protein Kinase Fact Book (71) provides protein sequence data for the three functional domains in literally hundreds of protein kinases, and this along with sequence information available in the primary literature,  
10 should greatly facilitate the further application of the present invention to the kinases. Similar information is available regarding other multi-substrate enzymes, which should facilitate their study and use according to the present invention.

Although the preferred method of the present invention involves the rational design of substrate analogs and mutant protein kinases, both could alternatively be made by use  
15 of methods known as combinatorial methods. There are many combinatorial methods of synthesizing organic compounds. Using one such method, one could synthesize nucleoside analogs on resin beads using sequential chemical steps, and then release them from the resin prior to phosphorylation to make the nucleotide triphosphates. After using such a method to make a collection or library of putative orthogonal  
20 substrates for mutants of v-Src kinase, other protein kinase, or other multi-substrate enzymes, the collection or library could be screened for particularly favorable binding or catalytic properties. This may allow for the more thorough search of structural, conformational, and electronic features of such putative orthogonal substrates. Moreover, it is often found that when larger numbers of analogs of a given substrate  
25 are investigated, and unexpectedly efficient substrate or inhibitor can be found. Furthermore, sometimes the compounds which are the most desirable would not have been chosen if only well understood parameters were used to specifically design the best compound.

There are also many combinatorial methods known in the art for making protein mutants. These include "error prone" polymerase chain reaction (PCR), "sexual" PCR, or PCR using primers with random nucleotides at fixed positions in the protein sequence. Other sequence randomization methods might include using chemical mutagens of cDNA or plasmid DNA, or MutD type strains of bacteria, which are known to introduce mutations randomly in proteins that they express. It would be possible to carry out the present invention by exploiting such methods for making randomly mutated protein kinases or other multi-substrate enzymes, and then screening for one with particularly high activity with a particular orthogonal substrate, or with some or all of the putative orthogonal substrates made using combinatorial synthesis, as described in the paragraph above. The assay methods described in the examples below would be suitable for this purpose, and those in the art would be readily able to design alternative approaches.

These methods and other methods which are or may be developed to explore protein sequence space and the structural space of small organic molecules might be particularly useful for the technological application described here, where we are changing or altering both the protein and the putative inhibitor in order to find the best possible non-natural (i.e., orthogonal) fit. The use of any of these or any of the other methods described herein would be within the scope of the present invention.

The synthesis of one engineered kinase is described in Example 4. The focus of this effort was on amino acid side chains that were within about 4Å of the N<sup>6</sup> of ATP; but there is nothing magical about that distance. Residues with side chains that are within about 1Å, 2Å, 3Å, 4Å, 5Å, 6Å, 7Å, 8Å, 9Å, 10Å, or lesser, greater or intermediate distances should also be considered as targets for modification. Amino acids with side chains that are within about 3Å to about 6Å would be preferred targets.

Generally those amino acids with the closer side chains will be preferred over those with more distant side chains, as they would be expected to cause the greatest steric or other interference with the orthogonal substituent on the inhibitor; and those with the

very closest side chains would be the most preferred.

Of course, there are many other ways to modify and express genetic sequences today than those used in the examples, such as site-directed mutagenesis, and we can expect that other methods will be developed in the future. The use of any or all of these would be within the scope of the present invention. In addition, although the use of genetic engineering is today probably the preferred method to prepare such mutants, it is not the only way. For example, one could design an engineered kinase and then synthesize that protein by known methods of chemical peptide synthesis. Or, it may be possible to chemically modify a given enzyme in a specific location such that one or more side chain changes in size, hydrophobicity, or other characteristic, such that it can more readily utilize an orthogonal substrate. The use of all such methods are within the scope of the invention.

Example 7 describes testing which could be done to determine whether the engineered kinase had retained its protein substrate specificity. It is preferred that the wild-type protein substrate specificity be substantially retained if, as in the examples, the goal is to use the engineered kinase to study what substrates the kinase acts upon and to what degree it does so, or it is to be used to replace or supplement the corresponding wild-type kinase *in vivo*, e.g., through genetic engineering. However, although for such purposes it is important that the kinase still recognize the same substrates as the wild type, it is not critical that it do so with the same kinetics; i.e., if it does so slower or faster, or to a greater or lesser degree, the engineered kinase may still have substantial value for such purposes. If the engineered kinase does not recognize the same protein substrates as the wild-type enzyme, it may have less value in studying the wild-type enzyme, but may still have substantial value in studying protein phosphorylation and kinases in general, and would still be within the scope of the invention.

Of course, the particular assays used in Example 7, although useful, need not be used. Those of skill in the art will readily be able to develop or adopt other assays that can

provide comparable information.

Once a mutant kinase has been made which accepts a given orthogonal substrate analog, or which is inhibited by a given inhibitor, it can be characterized using classical enzyme kinetic analysis, as illustrated in Examples 5 and 6. Also, as shown  
5 in Example 8, one can study the degree to which the mutant can utilize or be inhibited by the analog, and whether the analog is a "dead" (i.e., wholly ineffective) inhibitor for the wild-type enzyme. Of course, the methods used in the examples are not the only ways these studies can be done, and those of skill in the art can easily design alternate approaches.

10 As illustrated in Example 10, it is not necessary to make multiple amino acid substitutions to provide a mutant that will be inhibited by an inhibitor of the present invention. It may only be necessary to make a single amino acid change, as is the case with the mutants GST-XD4(I338A) and GST-XD4 (I338G).

#### **Assay to Identify Kinase Substrates**

15 A very simple embodiment of the present invention would be as follows. First, the orthogonal inhibitor is added to two samples of the cell of interest which either express an added gene for the engineered kinase or express the normal copy of the kinase of interest. The inhibitor can be added before after or during the activation of a  
20 signaling cascade (such as permeabilized cells, cell extracts, or cells that are naturally permeable to them). Then a method which allows detection of all phosphorylated proteins in a cell or cell fraction, *e.g.*, by using radioactive phosphorous [ $\gamma$ -<sup>32</sup>P]ATP or by using monoclonal antibodies specific for phosphorylated amino acids is used to reveal the result of specifically inhibition of the kinase of interest. In the cells  
25 expressing the normal copy of the kinase of interest, the protein substrates of the native kinase will become labeled, even in the presence of the inhibitor, whereas the protein substrates of the engineered kinase will at least be labeled to a lesser degree; preferably, the protein substrates of the engineered kinases will not be substantially

labeled, and most preferably, they will not be labeled at all.

It is also preferable if the wild-type kinase corresponding to the mutant has been removed from the cells, e.g., by "knock-out" of the cellular gene(s) for it. If the labeled proteins of such an assay are examined in tandem with control samples containing the wild-type kinase but not the mutant kinase, certain bands will be diminished in intensity in the mutant-treated sample relative to the control. Preferably, the difference in intensity will be high; most preferably, there will be bands which are missing in the mutant-containing samples treated with the inhibitor. This would indicate that the wild-type form of that kinase phosphorylates those differentially labeled proteins; when the kinase is inhibited, those bands do not get labeled.

Example 10 provides one example of a method of using a mutant kinase of the present invention, along with its orthogonal substrate analog or its inhibitor, as the case may be, to detect which are the intracellular protein substrates for that protein kinase. Developing such a test was a primary goal of the research that led to the present invention.

Generally, the method described in Example 10 and in FIG. 8 would appear to be generally applicable; however, there are many other possible approaches that could be used, once a mutant that accepts an orthogonal substrate analog or inhibitor has been prepared. The natural phosphate donor substrate is first prepared to contain a labeled moiety on the terminal phosphate, for example, by replacing the phosphate with [ $\gamma$ - $^{32}\text{P}$ ] phosphate. This substrate, along with the analog or inhibitor, is then added to a sample of lysed cells, cell extracts, permeabilized cells, or cells which are naturally permeable to the orthogonal nucleotide triphosphate substrate analog or to the inhibitor, and which express the mutant kinase, or to which the mutant kinase has been exogenously added (*e.g.*, by microinjection). After incubation under conditions that will allow the mutant kinase to become inhibited, and/or to phosphorylate its

protein substrates to the extent not inhibited, the labeled products are then extracted and analyzed in comparison with those produced by a control sample, which was treated substantially the same way, but without the addition of the analog or inhibitor, respectively. Methods for the detection of labeled proteins are well known, and include both quantitative and qualitative methods. In addition, all methods for characterizing and identifying proteins can be used to determine with specificity what the protein substrates are, and what their functions are. Ultimately, it should be possible to develop an understanding of what protein substrates each of the various protein kinases act upon, and reveal in great detail the mysteries of cellular signal transduction.

Once one or more cellular protein substrate has been identified, similar assays can be used to identify drugs or other compounds that can modulate the activity of a given protein kinase on one or more substrates. For example, one could add small amounts of solutions of a variety of such compounds to test samples containing cell-free extract, mutant kinase, along with a labeled orthogonal substrate analog and/or inhibitor. The labeled proteins can then be identified, e.g., by gel electrophoresis followed by autoradiography, and compared with a duplicate test sample treated the same way, but to which no drug or other compound was added.

If a protein is not labeled in a sample having an added compound plus substrate analog and/or inhibitor that does get labeled in a sample treated with the analog and/or the inhibitor, this indicates that the added compound has caused the kinase to phosphorylate a protein that it does not act on in the absence of the compound, *i.e.*, the compound upwardly modulates the activity of the kinase for that protein.

Alternatively, if a labeled protein appears in a test sample to which the compound or drug was added, but does not appear in a test sample not having the compound or drug added, this indicates that the added compound has prevented the kinase from phosphorylating a protein that it does act on in the absence of the compound, *i.e.*, the compound downwardly modulates the activity of the kinase for that protein substrate.

Furthermore, if quantitative measurements are made for each labeled protein, *e.g.*, by scanning autoradiograms and integrating the data, more subtle effect on kinase activity can be detected. For example, it may be found that a protein is more fully or less fully phosphorylated in the presence or absence of a given compound (*i.e.*, has been less dramatically modulated). It can also be expected that some compounds will upwardly modulate kinase activity for some proteins and downwardly modulate activity for others at the same time.

#### Use in Screening for Drug Design Target Kinases

As mentioned above, because kinases play key roles in various diseases, it is of great interest to develop inhibitors which can specifically inhibit a single wild-type kinase or group of wild-type kinases. By down-modulating the activity of these disease-involved kinases, it should be possible to reduce the disease symptoms, or even cure the disease.

However, the great difficulty which has been experienced in making such inhibitors of wild-type kinases, as briefly described above, limits the potential of that approach. The primary difficulty is finding inhibitors which are specific, and do not inhibit other kinases than the intended target. The reasons for such non-specificity are (i) the nucleotide triphosphate binding sites of kinases are highly conserved in evolution, and (ii) many kinases are "degenerate," that is, they have sufficiently similar activities and specificities that they can substitute for other kinases that because of gene deletion or other reason are absent or diminished in concentration in the cells. The problem of binding site similarities can in many instances be overcome, *e.g.*, by careful rational inhibitor design, or by selection of inhibitors from combinatorial libraries on the basis of specificity. However, efforts to do so with a kinase that is truly degenerate with another kinase will likely be unfruitful; either all of the co-degenerate kinases will be inhibited by even the best candidate compounds, or even if the target is inhibited, it will be impossible to tell, because a degenerate kinase will "take over" the activity of the inhibited one.



Because of this, there is a need for a way to screen kinases to determine which wild-type kinases are degenerate, and thus probably poor candidates for specific inhibition, and which are not degenerate, and therefore preferred candidates for specific inhibition. The present invention provides such a method. The present invention provides a means to generate a specific, unique kinase inhibitor for any kinase of interest, by making a mutant of the kinase that is specifically designed to be inhibited by candidate inhibitors selected, and then studying the effects of that inhibition.

One way to accomplish this is to test cells or cell extracts *in vitro*. For example, one could add ATP to such a sample which has one kind of label (the "first label") on the terminal phosphate, and add the specific inhibitor which is differently labeled (the "second label") at the terminal phosphate. The decrease in appearance of the second label on a given protein substrate (e.g., as viewed by gel electrophoresis) indicates specific inhibition of the mutant kinase; and appearance of the first label on that same substrate indicates that the other kinases have taken over that phosphorylation role, the degree of which is shown by the relative degree of such labeling. If it turns out that the engineered kinase is specifically inhibited, and other kinases do not take over phosphorylation of the substrates of the engineered kinase when it is inhibited, or at least do not completely take over, then that kinase is not degenerate, or at least not completely so; it is thus probably not a good candidate for development of a specific inhibitor of the wild-type for use as a drug to treat the disease it relates to. However, if inhibition of the mutant kinase with an inhibitor of the present invention is not compensated for by the other kinases, then it is a preferred candidate for the development of an inhibitor of the wild-type kinase.

Another, preferred method of such screening would be to produce animal models for the disease of interest, and then "knock out" the wild-type gene, and then, by genetic engineering, insert into the genome a gene encoding a mutant kinase of the present invention "knock-in". Then, an inhibitor of the present invention, preferably one which has been shown *in vitro* to inhibit the mutant, can be used to down-regulate the

mutant kinase. If down regulation leads to a decrease in the symptoms or morbidity of the disease in the model animal, or eliminates the disease, then that kinase is a preferred candidate for the development of a specific inhibitor of the wild-type form.

### **Gene Therapy Applications**

5 The mutant kinases and inhibitors of the present invention can also be used directly to treat diseases in humans and animals. Just as described above for the animal model systems, gene substitution could be used on patients with diseases which are mediated by those kinases. The wild-type gene for one or more such wild-type kinase would be deleted, e.g., by "knock-out" methods known in the art, and then specifically  
10 inhibitable mutants of those one or more kinases would be added to the animal's genome, e.g., by "knock-in" or gene therapy methods which are known in the art. Then, the inhibitor could be used as a drug to down-modulate those one or more mutant kinases, such that the disease is ameliorated to at least some degree, but the degree of activity of those kinases which may be found to be necessary for normal  
15 cellular function could be maintained. Of course, the kinases could also be essentially "turned off" by strong inhibition, if that proved to be therapeutically effective. Furthermore, if it is found that the disease is greatly improved or cured by a period of down-regulation or being turned off, then administration of the inhibitor could be discontinued, and the disease well might not return or exacerbate. If not, then  
20 inhibition could be discontinued on a long term or even permanent basis, and the mutants could be left to function in the place of the wild-type kinase for the remainder of that patient's life. Since the specific inhibitors of the present invention are not present in the environment, the mutant kinases should behave just like the wild-type (except to the extent that the engineering may have changed their activity or kinetics).  
25 And if the disease should recur or flare up again in the future, the patient could again be treated with the inhibitor, without the need to repeat the gene exchange.

### **Other Multi-substrate Enzymes**

As mentioned above, the present invention is not limited to mutant kinases,

orthogonal inhibitors, and their synthesis and use. The present invention will work just as well for other multi-substrate enzymes which covalently transfer part or all of one substrate, here called the donor, to another substrate, here called the recipient; and there are surely more such enzymes yet to be discovered. In any such instance, one of skill in the art who has studied the present specification will well appreciate the applicability of the present invention to such enzymes. The tasks at hand in such an instance are quite similar to those described in detail here for the kinases. First, it is necessary to identify what the donor substrate is, and/or to identify compounds which can inhibit that kinase, even if it is not specific for that kinase.

Second, it is necessary to consider where a bulky substituent might be added to the substrate or the inhibitor such that it will not bind as readily to the wild-type kinase, or preferably will not bind substantially to the wild-type kinase, and preferably, will not bind at all. Of course, it is not really necessary, in the case of kinases or in other multi-substrate enzymes as described above, to be restrictive with respect to which analogs of these to make; one can make a variety of them, even including some that seem unlikely to be ideal, and determine by screening which one or ones are the best. Further guidance regarding how to do this can be gained from the examples below. The inhibition assay, the results of which are shown in FIG. 6, is a non-limiting example of an assay particularly well suited to such screening.

The third step is to engineer the kinase such that one or more amino acid in the three-dimensional location where the bulky group would be expected to be if the analog did bind are replaced with amino acids having less bulky side chains, thus "making room" for the bulky moiety of the inhibitor. Steps two and three can, of course, be carried out in the reverse order.

For example, transferase enzymes would be most interesting candidates for study using the present invention. One could, following the teachings provided herein, prepare mutant transferases which will accept orthogonal inhibitors, and these could

be used together in order to identify the direct substrates of one particular transferase in a large family of homologous transferases, by the methods described above for the kinases. The family of methyl-transferases would be of clear interest, and could quite easily be studied using the methods provided herein. These enzymes all use the same nucleotide based cofactor, S-adenosylmethionine (AdoMet), as a methyl (CH<sub>3</sub>) group donor. The different members of the family can transfer the methyl group of AdoMet to a wide variety of cellular components such as proteins (in which case the methyl group is added to arginine, aspartate, and glutamate side chains), DNA (in which case the methyl group is added to the C-5 position of cytosine, or the N-7 of guanine), to components of cell membrane components such as phospholipids, and also to a number of small amine containing hormones. Many new targets are also being identified for this diverse family of enzymes. The present invention provides the opportunity to decipher the tremendously complex cellular mechanisms that these enzymes are carrying out.

For example, one could synthesize a set of AdoMet analogs that contain additional bulky hydrophobic groups at the N-6 position, or at other ring positions, which would make the analogs orthogonal, and thus not be accepted as readily by wild-type methyltransferases as is the natural substrate; and the structure in the region of the transferred methyl group might be altered such that the methyl group is more chemically resistant to transfer; or, for example, S-adenosylcysteine might be used as the starting compound instead. Using the crystal structures of DNA methyltransferase M.HhaI and the catechol methyltransferase catechol O-methyl-transferase (COMT), one can identify those amino acids in the adenine binding pocket which are candidates for mutation as we have done for the protein kinases; and one of ordinary skill in the art should readily be able to identify a set of residues to mutate in order to accommodate the bulky hydrophobic groups of one or more of the orthogonal substrates.

For example, one might mutate large hydrophobic groups to smaller alanine or glycine

residues, or replace hydrogen bonding amino acids with others that compliment the orthogonal purine analogs of AdoMet. Of course, a myriad of other possible mutations may work as well, and all would be within the scope of the present invention. In addition, from sequence alignments and crystal structures of methyltransferases, it is known that they have a common catalytic domain structure (70); so this approach is not limited to M.HhaI and COMT, but should be equally applicable to other methyl transferases.

After a methyltransferase mutant is identified which accepts an orthogonal inhibitor, radiolabeled AdoMet can then be synthesized which contains a C-14 labeled methyl group attached to the sulfur atom of AdoMet. When this radiolabeled analog is added to cells expressing one mutant methyltransferase, the direct substrates (e.g., protein or DNA, or polyamines) of all methyltransferases in the sample will be specifically radiolabeled with the C-14 methyl group. But when this is done in the presence of the orthogonal inhibitor, the specific substrates for the methyltransferase of interest will be less labeled in comparison to the sample not containing the inhibitor; preferably, they will not be substantially labeled, and most preferably, will not be labeled at all. In this way, or through the use of other methods described herein for the study of the kinases, direct substrates of methyltransferases can be identified which are important in cancer, embryonic development, chemotaxis of polymorphonuclear leukocytes, or in neurological disorders. In addition, the methods of the present invention can then be used to determining whether compounds can be identified that modulate the activity of the enzyme. The several other aspects of the present invention, although perhaps not described here, could also be applied to the methyl transferases, and also to other multi-substrate enzymes.

The forgoing discussion of the application of the present invention to the methyl transferases is not intended to limit the scope of the present invention, but to illustrate of the applicability of the present invention to multi-substrate enzymes other than the protein kinases. As will be appreciated by those in the art, the present invention could

be applied similarly to other multi-substrate enzymes using similar approaches.

### Terms

As is generally the case in biotechnology, the description of the present invention herein has required the use of a substantial number of terms of art. Although it is not practical to do so exhaustively, definitions for some of these terms are provided here for ease of reference. Definitions for other terms also appear elsewhere herein, and those are not repeated here. It is important to note that it is not intended that the terms defined here or elsewhere herein be given a meaning other than that which those skilled in the art would understand them to have when used in the field, and it is therefore urged that other sources also be consulted in interpreting the meaning of these terms and those defined elsewhere herein. However, the definitions provided here and elsewhere herein should always be considered in determining the intended scope and meaning of the defined terms.

The term "orthogonal" is used here to mean a compound that is similar, structurally and/or geometrically, to the natural substrate for a given enzyme, or to an inhibitor of the wild-type form of the enzyme, but has differences in chemical structure which make that compound less able to bind to the wild-type form of the enzyme than is the natural substrate. By "natural" substrate we mean that substrate which is utilized by the wild-type form of that enzyme. The orthogonal inhibitors of the present invention may be referred to in different ways herein; for example, sometimes they are referred to as "modified substrates," "modified inhibitors," "analogs," "derivatives," just as "substrates," or "inhibitors," and perhaps by other terms as well. However, in each instance, the same meaning is intended. Of course, the meaning of "orthogonal" and its synonyms are further explained in the descriptions of the invention provided above.

The putative orthogonal substrates and inhibitors of the embodiments of the invention described herein were made by adding bulky substituents to an atom on the natural substrate or known kinase inhibitor, respectively. However, the present invention is

not so limited. For example, it is possible to make an orthogonal substrate that is smaller than a known inhibitor or the natural substrate, *e.g.*, by preparing an analog that is missing one or more atoms or substituents that are present in the natural substrate. With such putative orthogonal substrates or inhibitors, one could mutate the enzyme to contain one or more amino acids having more bulky side chains than those found in the wild-type amino acid sequence, so that when the orthogonal substrate or inhibitor binds, those more bulky amino acid side chains fill or partially fill the extra space created by the missing atoms or substituents. In this way, it would be expected that the mutant would bind to and/or be inhibited by the orthogonal substrate or inhibitor, but would not substantially utilize the normal substrate, because the added bulky amino acids present a steric hinderance to its binding. Such an approach would allow for highly selective control of the resulting mutant.

It is important to keep in mind that even though the substrates and inhibitors of the examples herein are of the non-competitive type, this should not be viewed as a limitation of the scope of the present invention. Many different types of enzyme substrates and inhibitors are known, *e.g.*, competitive, non-competitive, uncompetitive, "suicide" inhibitors, etc. Competitive inhibitors compete with a substrate for its binding site; but since the inhibitor cannot participate in the catalytic reaction which that enzyme carries out, it slows down catalysis. Non-competitive inhibitors bind to the active site, but then become covalently or ionically bound to the protein structure of the enzyme, such that they cannot come off. Thus, they inhibit catalysis by taking molecules of enzyme out of the reaction altogether. More detailed descriptions of these and other competitive mechanisms can be found in a variety of sources (*e.g.*, 72). By applying the understanding of the art regarding such mechanisms to the design of inhibitors of the present invention, all such types of inhibitors could be made.

For example, an analog which can bind, but not react, would provide a competitive inhibition, and an analog which becomes covalently attached to the enzyme upon

binding, would be a non-competitive inhibitor, *i.e.*, a poison. All such types of inhibitors are within the scope of the present invention.

The term "homologous to" has been used to describe how information about how to modify one enzyme can be deduced from information regarding the three-dimensional structure of other, related enzymes. As those in the field well know, a part of one enzyme which is "homologous" to part of a second enzyme has a protein sequence which is related to that of the second enzyme. This relationship is that they have a number of amino acids in the same relative location to one another. For example, the imaginary sequence Asp-Met-Phe-Arg-Asp-Lys-Glu and the imaginary sequence Asp-Met-Ile-Arg-Glu-Lys-Asp have four amino acids in the same relative location, and three which are different, and they would be said to have homologous sequences.

Note that the three amino acids that are different between the chains are "conservative" differences, in that the substitutions in the second sequence relative to the first are with amino acids that have similar functionalities on their side chains. For example, Glu and Arg both have aliphatic side chains terminated in carboxylic acid groups, and both Phe and Ile are hydrophobic. Although this is often the case with homologous protein sequences, it need not be the case, and these two imaginary sequences would still be considered homologous even if the differences were not conservative.

Whether a particular sequence or domain is homologous to another cannot be stated with any particularity, *e.g.*, by using percentages, as there is no such absolute yardstick; we must leave it to the art to define which sequences are and are not considered "homologous." Reference 71 gives a good overview of which domains of the known kinases are considered by the art to be "homologous." In addition, although the art may not generally agree, it is intended here that sequences that are identical to one another also be considered to be "homologous" to one another.

The term "domain" is also one well known in the art, and it refers to a region in a



protein which has been identified as having a particular functionality. For example, the three domains in protein kinases have been discussed elsewhere herein, and their functional roles have been discussed. Often, as is the case with the kinases, different enzymes of the same family will have the same number of domains with each serving the same function, and they are often (but probably not always) arranged in the same order along the protein sequence. Interestingly, as is the case for the kinases, one enzyme may have a different length of protein sequence between its domains than does another. However, since the domains of two related enzymes are generally (but probably not always) homologous to one another, this does not generally hamper the identification of corresponding domains.

In describing the broader aspects of the present invention, the term "multi-substrate" is used. This is intended to mean enzymes which bind two or more substrates. Those multi-substrate enzymes of most interest here are those which catalytically attach at least part of one substrate to at least one other substrate. The kinases and the transferases are but two families of such multi-substrate enzymes, and those of skill in the art will readily recognize that there are other such enzymes and enzyme families.

The term "recognize" is sometimes used here to describe the ability of a substrate to specifically bind to the active site on an enzyme. This simply refers to the fact that an enzyme's substrate (or sometimes substrate derivatives or even completely different compounds that mimic the substrate) can contact and bind to the enzyme's active site, but other compounds will not. This concept is well known in the art. Enzymologists often say that the enzyme has an affinity for its substrate, or that the substrate has an affinity for the enzyme. They also say that an enzyme has "substrate specificity." These all really describe the same phenomenon.

A related term is the term "bind." An inhibitor generally binds, or sticks to, to an active site through one or more hydrophobic, hydrophilic, hydrogen, and/or ionic bonds, or, in the case of non-competitive inhibitors, through covalent bonds.

Although the complex understanding in the art regarding inhibitor binding and the reasons for inhibition may be of interest, such an understanding is not essential to understanding the present invention. It is sufficient to simply note that binding by an inhibitor causes inhibition of the catalytic reaction.

5 The terms "mutant" and "engineered form," when used to describe the enzymes of the present invention, simply mean that they have sequences that have a different amino acid at one or more position when compared to the sequence of the wild-type enzyme. In describing such mutants, two letters separated by a number indicate the amino acid mutations made. The letters are single-letter amino acid codes, and the numbers are  
10 the amino acid residue positions in the intact, wild-type enzyme. For example, GST-XD4 is a fusion protein containing a fragment, XD4, that has the same sequence as a specific part of the wild-type v-Src. In the designation GST-XD4(V323A, I338A), the valine in the sequence of v-Src fragment XD4 that represents position 323 in the complete wild type v-Src sequence has been replaced by alanine, and the isoleucine in  
15 the XD4 fragment that represents position 338 in the complete wild type v-Src sequence has also been replaced with alanine.

As described in the examples below, using the present invention we have designed, made and demonstrated the utility of a v-Src kinase which shows high specificity for a synthetic inhibitor while maintaining its wild-type specificity for tyrosine containing  
20 peptides and proteins, thus satisfying our initial research goals. By exploiting the highly conserved nature of the ATP binding site across the kinase superfamily and the availability of structural information from other protein kinases, we were able to engineer novel inhibition specificity for v-Src without any detailed structural information about v-Src itself. That we used an unrelated kinase as a blueprint for  
25 designing orthogonal ATP analogs to tag the direct cellular substrates of v-src. and have prepared inhibitors from like origins, demonstrates that this approach should work for other kinases as well.

## EXAMPLES

The following examples are provided to describe and illustrate the present invention. As such, they should not be construed to limit the scope of the invention. Those in the art will well appreciate that many other embodiments also fall within the scope of the invention, as it is described hereinabove and in the claims.

### EXAMPLE 1

#### Synthesis of ATP analogs

Twelve different orthogonal ATP analogs were synthesized. FIG. 2 is a schematic representation of their structure. The figure shows adenosine triphosphate (ATP), with an "X" bound to the 6 position; and in the box below, schematic representations are provided for the twelve side chains that take the place of "X" in each of the orthogonal ATP analogs described in the examples (which are always referred to by the numbers 1-12 set forth in bold typeface). Those analogs are:

- |   |  |
|---|--|
| 1- N <sup>6</sup> (methoxy)ATP            | 7- N <sup>6</sup> -(pyrrolidino)ATP    |
| 2- N <sup>6</sup> (ethoxy)ATP             | 8- N <sup>6</sup> -(cyclopentyl)ATP    |
| 3- N <sup>6</sup> (acetyl)ATP             | 9- N <sup>6</sup> -(cyclopentyloxy)ATP |
| 4- N <sup>6</sup> ( <i>i</i> -propoxy)ATP | 10- N <sup>6</sup> -(piperidino)ATP    |
| 5- N <sup>6</sup> -(benzyl)ATP            | 11- N <sup>6</sup> -(cyclohexyl)ATP    |
| 6- N <sup>6</sup> -(benzyloxy)ATP         | 12- N <sup>6</sup> -(cyclohexyloxy)ATP |

Analog **1**, **2**, **4**, **6**, **9**, and **12** were synthesized via Dimroth rearrangement of the corresponding N<sup>1</sup> alkoxy adenine derivatives in four steps starting from adenosine, according to the procedure of Fujii *et al.* (43). Analog **5** was synthesized similarly via Dimroth rearrangement of N<sup>1</sup> benzyladenosine (44). Analog **3** was prepared via *in situ* protection of the adenosine hydroxyl groups as trimethylsilyl ethers and subsequent treatment with acetyl chloride, according to McLaughlin *et al.* (45). Analog **7**, **8**, **10** & **11** were synthesized via treatment of 6-chloropurine riboside (Aldrich) with pyrrolidine, cyclopentylamine, piperidine & cyclohexylamine,

respectively (46).

Triphosphate synthesis was carried out according to the method of Ludwig (47) with the exception of the preparation of pyrophosphate. Accordingly, bis-tri-N-butyl ammonium pyrophosphate was prepared by mixing 1 equivalent of pyrophosphoric acid with 2 equivalents of tributyl amine in a (1:1) water: ethanol mixture until a homogenous solution was obtained. Solvent was removed under vacuum to dryness and the pyrophosphate was stored over  $P_2O_5$  overnight.

All non-radioactive nucleotides were characterized by  $^1H$ -NMR, mass spectral analysis and strong anion exchange (SAX) HPLC (Rainin # 83-E03-ETI).

$[\gamma\text{-}^{32}P]$   $N^6$ -(cyclopentyl)ATP was synthesized according the method of Hecht and Kozarich (48). The radiolabeled analog was purified by DEAE (A-25) Sephadex (Pharmacia) column chromatography and the triphosphate was identified by co-injection of the radiolabeled material with an authentic sample of  $N^6$ -(cyclopentyl) ATP on an SAX-anion exchange HPLC column (Rainin) (linear gradient of 5-750 mM ammonium phosphate pH 3.9 in 10 min. at 0.5 mL/min). The chemical yield of the reaction varied from 70% to 80%.

## EXAMPLE 2

### Screening of Nucleotide Analogs

To identify compounds that would not be accepted as substrates by any existing cellular kinases (53), we screened a panel of synthetic A\*TP analogs in a murine lymphocyte lysate (CF) rich in protein tyrosine kinases(13).

The assays were performed using spleenocytes (8-30 week old male and female C57/B6 mice from the Princeton University Animal Facility) which were isolated and washed in RPMI-1640 medium containing 5% Bovine Calf Serum (BCS), 1% HEPES and DNaseI (1 $\mu$ g/ml). Red cells were lysed at 4°C by treatment with 17 mM tris

ammonium chloride pH 7.2. The cells were hypotonically lysed on ice for 10 min. in 1mM Hepes pH 7.4, 5 mM MgCl<sub>2</sub>, leupeptin (10 µg/ml), aprotinin (10 µg/ml) and 100µM PMSF according to the method of Fukazawa *et al.* (51). After vortexing and centrifugation at 500xg, the supernatant was collected. Cells were stored at 4°C for 20 min. to attenuate the basal protein phosphorylation level, after which the buffer was adjusted to 20 mM Hepes pH 7.4, 10 mM MgCl<sub>2</sub> and 1 mM NaF. Sodium vanadate (100 µM) was then added to inhibit the activity of phosphotyrosine phosphatases.

Each nucleotide triphosphate was added to a final concentration of 100 µM to 5 x 10<sup>6</sup> cell equivalents and incubated at 37°C for 5 min. after which 4X Laemmli gel loading buffer was added to the cell lysate to quench the reaction. Proteins were separated by 12.5% SDS-PAGE and transferred to Protran BA85 (Schleicher-Schuell). The blot was probed with the anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology) and the bound antibody was detected via enhanced chemiluminescence (cat. 34080, Pierce) following treatment with HRP- coupled goat-anti-mouse antibody (VWR cat. 7101332) according to the manufacturer's instructions.

The results are shown in FIG. 3, which is an anti-phosphotyrosine protein immunoblot showing the level of protein tyrosine phosphorylation following treatment of a murine lymphocyte cell lysate (CF) with 100 µM of ATP or A\*TPs (1-12). The cell lysate used includes the tyrosine kinases Src, Fyn, Lck, Lyn, Yes, Fgr, Hck, Zap, Syk, Btk, Blk, and other tyrosine kinases present in B and T lymphocytes, macrophages, and follicular dendritic cells (13). Molecular size standards (in kilodaltons) are indicated. The A\*TPs containing the smallest N<sup>6</sup> substituents, 1 (methoxy), 2 (ethoxy), and 3 (acetyl) showed some ability to serve as cellular tyrosine kinase substrates (Fig. 3, lanes 3-5). The A\*TPs with sterically demanding N<sup>6</sup> substituents, 4 (*i*-propoxy), 5 (benzyl), and 6 (benzyloxy), and all analogs containing cyclic aliphatic substituents (7-12) showed little or no protein phosphorylation (Fig. 3, lanes 6-8, 11-16).

To test for possible metathesis of orthogonal A\*TPs (7-12) with cellular ADP to give A\*DP and ATP, we added 1mM ADP to cell lysate kinase reactions identical to those shown in FIG. 3; (data not shown); the pattern of phosphoproteins was the same, indicating that no significant metathesis of A\*TP occurs in a complete cell lysate system.

Based upon these results, it appears that analogs (7-12) are "dead substrates" for wild type tyrosine kinases, i.e., the wild-type substrates do not substantially, or at all, accept these as phosphate donor substrate. These analogs thus were chosen as the most preferred targets for reengineering the nucleotide binding site of v-Src.

### EXAMPLE 3

#### Designing the Mutant v-Src

No crystal structures of any tyrosine kinases in an active conformation have been solved to date although several structures of inactive kinases have been solved (54,55). However, two crystal structures of catalytically active ser/thr kinases have been solved (56,57). There is a high degree of functional homology between the ser/thr and the tyrosine kinase catalytic domains as shown by affinity labeling of the identical catalytically active lysine residue in both kinase families (K72 in cAMP dependent kinase (PKA), K295 in v-Src) (58,58). Inspection of the PKA (56) and cyclin dependent kinase-2 (CDK2)-cyclinA (57) crystal structures revealed two amino acid side chains within a 4 Å sphere of the N<sup>6</sup> amino group of bound ATP: V104/M120 (PKA) and V64/F80 (CDK2) (60).

FIG. 4 shows a close-up view of the ATP binding site in cAMP dependent protein kinase (PKA), which is bound to ATP. **Three** residues within a 4 Å sphere of the N<sup>6</sup> amine of ATP (Val104, Met120, and Glu121) and the catalytically essential lysine residue (Lys72) are shown in ball-and-stick representation. The remainder of the protein is shown in ribbon format. This figure was created by feeding the output of Molscript into the Raster3D rendering program (68,69). Note that in the model, the

side chain of Glu121 is pointed away from the adenine ring binding region, and therefore Glu121 was not a candidate for alteration.

The sequence alignment of the ATP binding regions of PKA (SEQ. ID. NO. 1), CDK2 (SEQ. ID. NO. 2), and v-Src (SEQ. ID. NO. 3) are shown below. The residues shown in bold correspond to the amino acids with side chains in a 5Å sphere of the N<sup>6</sup> amino group of kinase bound ATP.

<u>Subdomain</u>	IV	V
PKA (SEQ. ID. NO. 1)	(99)NFPFLVKLEFSFKDNSNLYMVMEYVPG(125)	
CDK2 (SEQ. ID. NO. 2)	(59)NHPNIVKLLDVIHTENKLYLVFEFLHQ(85)	
v-Src (SEQ. ID. NO. 3)	(318)RHEKLVQLYAVVSE-EPIYIVIEYMSK(343)	

Based on the functional similarity between the above-described kinases, we decided to mutate positions V323 and I338 in the v-Src catalytic domain, which correspond to V104/M120 in PKA & V64/F80 in CDK2. By mutating these residues to alanine, we hoped to create an additional "pocket" in the nucleotide binding site of v-Src to allow binding of one of the preferred orthogonal A\*TPs (4-12).

#### EXAMPLE 4

##### Mutant Synthesis, Expression and Purification

The mutant (V323A,I338A) was made as described below. Both the wild-type and the double alanine mutant of the v-Src catalytic domain, (the XD4 fragment) were made as glutathione S-transferase (GST) fusion proteins (GST-XD4) (61,62). These were made in *E. coli*, which is a good expression host because it lacks any endogenous tyrosine kinases, as described in the following Example. We used the XD4 fragment of v-Src because it contains an intact SH1 catalytic domain but lacks the non-catalytic regulatory SH3 and SH2 domains, and exhibits higher specific activity than full-length v-Src.

Overlap extension PCR was used to make GST-XD4 (V323A, I338A) (49). Pfu polymerase (Stratagene) was used in the PCR reactions according to the manufacturer's protocol. Six synthetic oligonucleotides were used:

SEQ. ID NO. 4 (5'-TTTGGATCCATGGGGAGTAGCAAGAGCAAG),  
SEQ. ID NO. 5 (5'-TTTGAATTCTACTCAGCGACCTCCAACAC),  
SEQ. ID NO. 6 (5'-TGAGAAGCTGGCTCAACTGTACGCAG),  
SEQ. ID NO. 7 (5'-CTGCGTACAGTTGAGCCAGCTTCTCA),  
SEQ. ID NO. 8 (5'-CTACATCGTCGCTGAGTACATGAG),  
SEQ. ID NO. 9 (5'-CTCATGTACTCAGCGACGATGTAG).

Primer SEQ. ID NO. 4 contains a *Bam*H1 site and primer SEQ. ID NO. 5 contains an *Eco*R1 site (shown in italics). Primers SEQ. ID NO. 6 and SEQ. ID NO. 7 contain the nucleotide sequence changes to introduce the V323A mutation (nucleotides encoding mutations are shown in bold). Primers SEQ ID NO. 8 and SEQ. ID NO. 9 contain the I338A mismatch.

The XD4 gene from YEp51-XD4 plasmid (a gift of B. Cochran at Tufts Medical School) was amplified with primers SEQ. ID NO. 4 and SEQ. ID NO. 5. The PCR product was digested with *Bam*H1 and *Eco*R1 and ligated into *Bam*H1 and *Eco*R1-digested pGEX-KT and then transformed into the *E. coli* strain DH5 $\alpha$ .

The GST-XD4 (V323A) was constructed using primer SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7 with the GST-XD4 plasmid as the template. The PCR product from the two step procedure was digested with *Bam*H1 and *Eco*R1, ligated into *Bam*H1 and *Eco*R1-digested pGEX-KT, and transformed into DH5 $\alpha$  *E. coli* cells. GST-XD4 (V323A, I338A) was made in the same manner using primers SEQ. ID NO. 8 & SEQ. ID NO. 9 with GST-XD4 (V323A) as the template.

Expression and purification of the GST fusion kinases were carried out in *E. coli*



strain DH5 $\alpha$  as described by Xu *et al* (50), with the exception that the cells were stored at 4°C overnight prior to centrifugation and lysis by French press (overnight storage is essential for producing highly active kinases).

5 Expression of 6-His-XD4 and 6-His-XD4 (V323A, I338A) in Sf9 insect cells was accomplished using the Life Technologies BAC-to-BAC system. Briefly, the 6-His-XD4 and 6-His-XD4 (V323A, I338A) genes were generated by PCR using the corresponding pGEX vectors as templates with primers SEQ. ID NO. 4 and SEQ. ID NO. 5, followed by digestion with *Bam*H1 and *Eco*R1. The resulting PCR fragment was cloned into pFASTBAC which had been digested with *Bam*H1 and *Eco*R1.

10 Transformation of HB10BAC cells and subsequent transfection of Sf9 cells with the Bacmid containing XD4 or XD4 (V323A, I338A) were carried out as suggested by the manufacturer.

15 In an alternate procedure performed herein, transfection of v-src or v-src(I338G) mutant kinase was performed by cloning the v-src gene from the pGEX-v-Src vector(4) into the pBabe vector(5) which contains the Itr promotor for high level of expression in NIH 3T3 cells. The pBabe v-Src (I338G) plasmid was transfected into viral packaging cell line BOSC 23(6) and viral particles harvested after 2 days as described(6). NIH 3T3 cells were infected as described(7) with these viral particles and stable transfectants were selected in puromycin containing media as described(5).  
20 Stable transfectants were maintained in media containing puromycin to ensure no loss of expression of v-Src.

25 The final results are shown in FIG. 1, which is a diagram showing the domain structure of v-Src including the Src-homology 3, 2, and 1 (SH3, SH2 & SH1) domains, with the domain boundaries indicated by the amino acid residue numbers listed above each boxed domain. The domain structure of XD4 is also represented, which contains a deletion of residues 77-225 ( $\Delta$ 77-225). Domain organizations of the glutathione S-transferase (GST) fusion with XD4 (numbering from v-Src), and the

doubly mutated GST-XD4 (representing both V323A, I338A and I338G) are also shown schematically.

### EXAMPLE 5

#### Testing the Mutant v-Src For Ability to Bind Orthogonal ATP Analogs

We next evaluated the ability of the  $N^6$  substituted ATP analogs (1-12) to differentially inhibit wild-type and mutant kinase phosphorylation of RR-Src with [ $\gamma$ - $^{32}$ P] ATP, which is a measure of their ability to bind to the respective ATP binding sites. Assays were carried out in triplicate at 37°C in a final volume of 30  $\mu$ L buffered at pH 8.0 containing 50 mM Tris, 10 mM  $MgCl_2$ , 1.6 mM glutathione, 1 mg/mL BSA, 1 mM RR-Src peptide with either GST-XD4 (100 nM) or GST-XD4(V323A, I338A) (100 nM) and 10  $\mu$ M [ $\gamma$ - $^{32}$ P] ATP (1000 cpm/pmol) [Dupont NEN]. Cold ATP or A\*TP analogs (100  $\mu$ M) (1-12) were added prior to addition of the kinase. After 30 minutes the reactions were quenched by spotting 25  $\mu$ L of the reaction volume onto p81 phosphocellulose disks (Whatman) and these were immersed in 250 mL of 10% acetic acid for >30 minutes followed by washing and scintillation counting according to standard methods (52).

The results are shown in FIG. 1. Relative inhibition of GST-XD4 is shown by solid bars, and relative inhibition by GST-XD4(V323A, I338A) is represented by the diagonal filled bars. Percent inhibition  $(1 - v_1/v_0)$  is reported as a ratio of  $v_1$  (cpm in the presence of 100  $\mu$ M of the indicated triphosphate and 10  $\mu$ M [ $\gamma$ - $^{32}$ P] ATP (1000 cpm/pmol)/ $v_0$  (cpm in the presence of 10  $\mu$ M [ $\gamma$ - $^{32}$ P] ATP (1000 cpm/pmol) alone - background cpm due to non-specific 10  $\mu$ M [ $\gamma$ - $^{32}$ P] ATP binding to the phosphocellulose disks (<0.1% of total input counts)). Error bars represent the S.D. determined from four separate experiments with three replicates.

The wild-type kinase GST-XD4 displays poor binding affinity for most A\*TP analogs (FIG. 6, solid bars) as expected from the lymphocyte kinase assay (FIG. 3). In contrast, the doubly mutated GST-XD4(V323A, I338A) shows excellent inhibition by

more sterically demanding  $N^6$  substituted ATP analogs (Fig. 6, shaded bars). Most significantly, the GST-XD4(V323A, I338A) mutant is inhibited by ATP analogs 5, 8, 9, and 11 almost as well as the wild-type kinase, GST-XD4, is inhibited by its natural substrate ATP. We have confirmed that GST-XD4(V323A, I338A) and the full length GST-v-Src(V323A, I338A) display the same inhibition pattern with A\*TPs (1-12) (data not shown).

Four of the nine “dead” substrates identified in the screen of wild-type kinase specificity (FIG. 3) bind well to the mutant kinase. This high success rate in identifying new substrates for a mutant v-Src which are not accepted by wild-type kinases suggests that we have identified a key feature of the v-Src nucleotide binding site, namely the residues which make a close fit around the  $N^6$  amino group of ATP. It is worth noting that we know of no wild-type protein kinases which contain an alanine at the position corresponding to I338 in v-Src (position 120 in PKA). If a sterically demanding amino acid side chain at this position also plays a critical role in determining the specificity of other kinases, it should well be possible to engineer them to accept orthogonal substrates using an approach very similar to the one described here, and such engineered kinases would be well within the scope of the present invention.

#### EXAMPLE 6

##### Determining Catalytic Efficiency of Mutant v-Src with the Most Preferred Orthogonal ATP Analog

We chose to test the ability of  $N^6$ -(cyclopentyl) ATP, 8, to serve as a catalytically competent substrate of both wild-type GST-XD4 and the GST-XD4(V323A, I338A) mutant over the other three ATP analogs 5, 9, and 11 because analog 8 exhibited a slightly lower level of phosphorylation with wild-type kinases (Fig. 3, lane 12).

ATP and  $N^6$ -(cyclopentyl)ATP dependent RR-Src phosphorylation (1 mM) by GST-XD4 (V323A, I338A) and GST-XD4 were carried out at low substrate conversion (<

5%) in triplicate. Kinetic constants were determined by analysis of Lineweaver-Burk plots of the rate data (64). Assays were carried out in triplicate at 37°C in a final volume of 30  $\mu$ L buffered at pH 8.0 containing 50 mM Tris, 10 mM  $MgCl_2$ , 1.6 mM glutathione, 1 mg/mL BSA, 1 mM RR-Src peptide with either GST-XD4 (100 nM) or GST-XD4(V323A, I338A) (100 nM) and 10  $\mu$ M [ $\gamma$ - $^{32}P$ ] ATP (1000 cpm/pmol) or [ $\gamma$ - $^{32}P$ ]  $N^6$ -(cyclopentyl)ATP (5000 cpm/pmol) as indicated.

Table 1

Kinetics for Phosphate Donor Substrates

Nucleotide	GST-XD4			GST-XD4(V323A, I338A)		
	$K_{cat}$ ( $min^{-1}$ )	$K_M$ ( $\mu M$ )	$K_{cat}/K_M$ ( $min^{-1}M^{-1}$ )	$K_{cat}$ ( $min^{-1}$ )	$K_M$ ( $\mu M$ )	$K_{cat}/K_M$ ( $min^{-1}M^{-1}$ )
ATP	$2 \pm 0.5$	$12 \pm 3$	$1.6 \times 10^5$	$0.8 \pm 0.2$	$150 \pm 20$	$5.3 \times 10^3$
$N^6$ -(cyclo- pentyl)ATP	$2000(K_I)$		$(5 \pm 2) \times 10^{-2}$	$15 \pm 3$	$3.3 \times 10^3$	

As shown in Table 1 above, the wild-type kinase GST-XD4 did not substantially phosphorylate the RR-Src peptide with [ $\gamma$ - $^{32}P$ ]  $N^6$ -(cyclopentyl) ATP, confirming our previous observations that this analog is not a significant substrate for the wild-type kinase. In contrast, GST-XD4(V323A, I338A) displayed Michaelis-Menten kinetics with the orthogonal A\*TP, [ $\gamma$ - $^{32}P$ ]  $N^6$ -(cyclopentyl) ATP. The  $K_M$  of the mutant for the orthogonal substrate is quite close to the  $K_M$  of GST-XD4 for ATP. On the other hand, the mutant has a  $K_M$  for ATP which is more than 10-fold higher than the  $K_M$  of GST-XD4 for ATP.

The parameter used to rank catalysts for competing substrates is the ratio of the turnover number to the Michaelis-Menten constant,  $k_{cat}/K_M$  (the "specificity constant") (64). The  $k_{cat}/K_M$  of the engineered mutant GST-XD4(V323A, I338A) with

the orthogonal substrate  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  is only 50-fold lower than the  $k_{\text{cat}}/K_{\text{M}}$  value of the wild-type kinase with its natural substrate, ATP. This catalytic efficiency with the orthogonal A\*TP substrate, coupled with the mutant kinase's lower catalytic efficiency with ATP when compared to the wild-type, satisfy two of the design criteria discussed above.

It is even more significant that the new substrate,  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$ , is not substantially utilized by wild-type GST-XD4, as demonstrated by the apparent complete inability of GST-XD4 to use this analog as a phosphodonor for autophosphorylation; this is illustrated in FIG. 5© lane 3. FIG. 5© is an autoradiogram showing  $[\gamma\text{-}^{32}\text{P}]$  ATP dependent autophosphorylation of GST-XD4, lane 1, or GST-XD4(V323A, I338A), lane 2; and  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  dependent phosphorylation of GST-XD4, lane 3, or GST-XD4(V323A, I338A) phosphorylation, lane 4. Note that in contrast to GST-XD4, the engineered kinase is efficiently autophosphorylated with  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  (Fig. 5(c), lane 4).

## EXAMPLE 7

### Confirming Retention of Protein Substrate Specificity

As shown in Table 2 below, we have found that the wild-type GST-XD4 kinase phosphorylated a well characterized peptide substrate of v-Src, RR-Src, with kinetics consistent with literature reports (63). This indicates that the sequence engineering had not substantially affected the catalytic activity of the enzyme with respect to its protein substrates.

Table 2

Kinetics for Protein Substrate RR-Src

	<u>GST-XD4</u>	<u>GST-XD4(V323A, I338A)</u>
Nucleotide	$K_{\text{M}}$ (mM)	$K_{\text{M}}$ (mM)

(Saturated)

---

ATP	2.6±0.9	3.1±0.9
N <sup>6</sup> -(cyclo-pentyl)ATP	----	2.1±0.9

---

Assays of GST-XD4 and GST-XD4(V323A, I338A) phosphorylation of RR-Src were carried out in triplicate at 37°C in a final volume of 30 µL buffered at pH 8.0 containing 50 mM Tris, 10 mM MgCl<sub>2</sub>, 1.6 mM glutathione, 1 mg/mL BSA, 1mM RR-Src peptide with either GST-XD4 (100 nM) or GST-XD4(V323A, I338A) (100 nM) and 10 µM [ $\gamma$ -<sup>32</sup>P] ATP (1000 cpm/pmol) [Dupont NEN].

To determine whether the alanine mutations have any effect on the protein substrate specificity, we measured the K<sub>M</sub> of both the wild-type and the mutant fusion proteins for the RR-Src peptide. At saturating concentrations of [ $\gamma$ -<sup>32</sup>P] ATP the wild-type and the mutant display essentially the same K<sub>M</sub> for RR-Src, 2.6 ± 0.9 mM and 3.1 ± 0.9 mM, respectively (63). In addition, the K<sub>M</sub> of the mutant for the protein substrate in the presence of saturating amounts of the orthogonal substrate was also essentially the same, 2.1±0.9 mM. These findings suggest that the alanine mutations in the ATP binding pocket, which is proximal to the adjacent phospho-acceptor binding site, do not affect the protein target specificity.

In support of this, the engineered kinase phosphorylates the same broad set of proteins that are phosphorylated by wild-type XD4 when each is expressed in Sf9 insect cells. This is shown in the FIG. 5(a), which shows an anti-phosphotyrosine protein blot of cell lysates (10<sup>8</sup> cell equivalents/lane) from Sf9 insect cells expressing 6-His-XD4, lane 2, or 6-His-XD4 (V323A, I338A), lane 3. These blots were carried out following lysis of 10<sup>6</sup> cells in a buffer containing 0.1% Triton-X-100, 50 mM Tris, pH 8.0, using a procedure similar to that of the blots of Example 2.

The Sf9 insect cell system is a good host for expressing small amounts of tyrosine kinases because these cells contain most of the same machinery necessary to carry out post-translational modifications to proteins resulting in kinases which are more similar in activity to those found in mammalian cells. Furthermore, uninfected Sf9 cells lack endogenous tyrosine kinase activity, as shown in FIG. 5(a), lane 1, and thus the phosphotyrosine containing proteins in lanes 2 and 3 of FIG. 5(a) are substrates of the expressed 6-His-XD4 or mutant 6-His-XD4 kinases. We attribute the small differences in phosphorylation level of particular proteins to the lower catalytic activity of the mutant XD4 (V323A, I338A) compared to the wild-type kinase.

Taken together, these data show that the peptide specificity of the engineered kinase is virtually identical to that of wild-type v-Src.

### EXAMPLE 8

#### **Confirmation that the Engineered Kinase Accepts the Preferred Orthogonal Substrate, but the Wild-Type Kinase Does Not Substantially Accept It**

The ultimate goal of this work is to use mutant kinases specific for synthetic substrate analogs to tag the direct protein substrates in whole cells or cell lysates. For this it is preferable that no wild-type kinase, including ser/thr specific kinases (which carry out the bulk of cellular phosphorylation, as only 0.03% of all phosphoamino acids are tyrosine) (65), substantially accept the synthetic substrate. To establish that  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  is essentially a "dead substrate" for *all* wild-type cellular kinases, *in vitro* kinase reactions with  $[\gamma\text{-}^{32}\text{P}] \text{ATP}$  or  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  were performed with murine lymphocyte lysates.

These assays were performed in a manner similar to the procedure set forth in Example 2, with the exception of the use of radiolabeled  $[\gamma\text{-}^{32}\text{P}] \text{ATP}$  or  $[\gamma\text{-}^{32}\text{P}] \text{N}^6\text{-(cyclopentyl)ATP}$  (5000 cpm /pmole) added to a final concentration of 100  $\mu\text{M}$  with  $5 \times 10^6$  cell equivalents and incubated at 37°C for 10 min., after which 4X Laemmli gel loading buffer was added to the cell lysate to quench the reaction. Proteins were

separated by 12.5% SDS-PAGE. The gel was soaked in 10% acetic acid, 10% isopropanol for 1 h. after which it was dried in a gel dryer and exposed to Biomax MS film (Kodak # 111-1681) for 1 h.

The results are shown in FIG. 5(b), which is an autoradiogram showing the level of phosphorylation in hypotonically lysed murine lymphocytes with [ $\gamma$ - $^{32}$ P] ATP, lane 1 or [ $\gamma$ - $^{32}$ P]  $N^6$ -(cyclopentyl) ATP, lane 2. There are no radiolabeled phosphoproteins in the cell lysate following addition of [ $\gamma$ - $^{32}$ P]  $N^6$ -(cyclopentyl)ATP, confirming the true orthogonal nature of  $N^6$ -(cyclopentyl)ATP with respect to all wild type protein kinases. The same result was found when *in vitro* kinase reactions with [ $\gamma$ - $^{32}$ P] ATP or [ $\gamma$ - $^{32}$ P]  $N^6$  (cyclopentyl)ATP and NIH 3T3 cell lysates were used instead of freshly isolated murine lymphocytes (not shown).

In principle, the ability to follow one protein kinase's activity in the presence of all other cellular kinases would allow for the identification of the direct kinase targets in a particular cell type. To accomplish this we are currently using membrane permeabilization (66) and a cell permeable form of A\*TP to introduce [ $\gamma$ - $^{32}$ P] A\*TP into cells (67).

## EXAMPLE 9

### Construction and Analysis of Single Mutation v-Src Mutants

In order to determine whether a single mutation might be sufficient to allow  $N^6$ -(cyclopentyl)ATP to be efficiently used as a substrate, three additional v-Src derived mutants were prepared, using methods comparable to those of Example 4. However, these had only single mutations, at position 338. These were again expressed as GST-XD4 fusion proteins. These mutants, GGST-XD4(I338A), GST-XD4(I338S) and GST-XD4(I338G), were then tested as described in Example 8.

The results are shown in FIG. 7. The gel lanes shown on the top left of FIG. 7 show that the mutant with alanine at the 338 position was able to utilize the natural



substrate, ATP, more readily than the mutant with serine at that same position. The gel lanes shown on the bottom left of FIG. 7 show that the mutant with alanine in position 338 is also better able to use ATP as a substrate than is the mutant with glycine at that position.

5 The panels on the right side of FIG. 7 tell an even more interesting story. From the top right panel, it is clear that the mutant with serine at position 338 is not able to utilize  $\text{N}^6$  (cyclopentyl)ATP nearly as well as is the mutant with alanine at that position. However, the bottom panel shows that the mutant with glycine at position 338 is better able to use  $\text{N}^6$  (cyclopentyl)ATP as substrate than is the mutant with  
10 alanine at that position.

These results are most promising. It appears that a single mutation is enough to allow the use of this orthogonal substrate. Notably, the mutant with glycine at position 338 appears to be the best engineered v-Src mutant that we have produced to date.

Moreover, it is quite surprising that a glycine substitution would work here.

15 Generally, glycine substitution is usually not expected to work in such situations, because it introduces too much flexibility into the enzyme structure, and thus detrimentally affects the desired outcome.

## EXAMPLE 11

### Identifying the Substrates of v-Src

20 A schematic representation of an experimental approach to identifying v-Src substrates is shown in FIG. 8. The engineered v-Src, such as GST-XD4(V323A, I338A), is added to cell extracts or permeabilized cells, along with a radiolabeled orthogonal substrate, such as  $[\gamma\text{-}^{32}\text{P}] \text{N}^6$  (cyclopentyl)ATP. Typically, this would be done in triplicate. After incubation, the cells would be lysed (if not already lysed),  
25 and the resulting samples would be separated by polyacrylamide gel electrophoresis. A western blot taken from the gel and labeled with anti-phosphotyrosine would show

all phosphorylated proteins in the sample; and an autoradiogram of the gel would reveal which of those were phosphorylated by v-Src.

## EXAMPLE 12

### Synthesis of inhibitors

5 The pyrazolopyrimidine backbone for the first six inhibitors is shown in FIG. 11A. Synthesis of 4-amino-1-tert-butyl-3-phenylpyrazolo [3,4-d]pyrimidine, having a phenyl group in the "R" position, compound 1 (which is the same structure as PP1, shown on Fig. 10, but without the para-methyl group on the phenyl ring) was carried out according to the method of Hanefeld et. al.(76). Compounds 2-6 (FIG. 11B),  
10 having cyclobutoyl, cyclopentoyl, cyclohexoyl, benzoyl, and 2-furoyl substituents at the "R" position, respectively, were synthesized by treatment of 1 with cyclobutoyl chloride, cyclopentoyl chloride, cyclohexoyl chloride, benzoyl chloride, or furoyl chloride, respectively in dry pyridine for one hour at room temperature. The structures of each of the substituents are shown in Fig. 11B. Purification by silica gel  
15 chromatography afforded pure products in 16-84% yield. Compounds 1-6 were characterized by <sup>1</sup>H-NMR and mass spectral methods.

## EXAMPLE 13

### Screening of inhibitors which are orthogonal to wild-type kinases

20 To identify compounds that would not inhibit any existing cellular kinases, we screened the panel of synthetic pyrazolo pyrimidine analogs (1-6) against two closely related purified tyrosine kinases, v-Src and Fyn, in a peptide phosphorylation assay using [ $\gamma$ -<sup>32</sup>P]ATP as the radiolabel tracer of kinase activity, as described in Shah et. al. (79).

25 The results showed that each of the compounds 2-6 had IC<sub>50</sub> values of over 400  $\mu$ M for inhibition of Src and compounds 3 and 5 showed at over 400  $\mu$ M IC<sub>50</sub> values for inhibition of wild-type Fyn, indicating that these analogs (2 and 5) are orthogonal to (do not inhibit) these representative wild-type kinases.

**EXAMPLES 14-16**

Deconvoluting protein kinase signaling pathways using conventional genetic and biochemical approaches has been difficult due to the overwhelming number of closely related kinases. If cell permeable inhibitors of each individual kinase could be designed, the role of each protein kinase could be systematically assessed.

**Results:** We have devised an approach combining chemistry and genetics to develop the first uniquely specific cell permeable inhibitor of the oncogenic protein tyrosine kinase, v-Src. A functionally silent active site mutation was made in v-Src in order to distinguish it from all other cellular kinases. A tight binding ( $IC_{50}$ = 430 nM) cell permeable inhibitor of this mutant kinase was designed and synthesized which does not inhibit wild-type kinases. *In vitro* and whole cell assays established the unique specificity of the mutant v-Src/inhibitor pair. This inhibitor reverses the transforming effects of cellular expression of the engineered v-Src, but does not disrupt wild type v-Src mediated cellular transformation. These cell lines differ only by a single amino acid in a single protein kinase, establishing that dramatic changes in cellular signaling can be directly attributed to specific inhibition of the engineered kinase. The generality of this method was tested by engineering another tyrosine kinase, Fyn, to contain the corresponding silent mutation. The same compound was found to be a potent inhibitor ( $IC_{50}$ =830 nM) of this mutant kinase as well, confirming the generality of the strategy toward making allele specific inhibitors of multiple tyrosine kinases.

**Conclusions:** Allele specific cell permeable inhibitors of individual Src family kinases can be rapidly developed using a combined chemical and genetic approach. Treatment of mutant v-Src transformed NIH 3T3 fibroblasts with a uniquely specific v-Src reverts the morphological hallmarks of transformation. The inhibitor exhibits no effect on cells transformed by the wild-type v-Src allele strongly suggesting that the phenotype induced by inhibitor treatment is a result of a single inhibitory event. The ability to rapidly generate kinase specific inhibitors in a generalizable way will be

useful for deconvolution of kinase mediated cellular pathways and for validating novel kinases as good targets for drug discovery both *in vitro* and *in vivo*.

As stated earlier, a combined chemical and genetic strategy has been devised which allows for the generation of "chemical sensitive" mutant kinases which are uniquely inhibited by a rationally designed small molecule inhibitor. Our approach involves engineering a unique pocket in the active site of the kinase of interest with a functionally silent mutation. A specific inhibitor of the engineered kinase is then synthesized by derivatizing a known kinase inhibitor with a bulky group designed to fit the novel active site pocket. The bulky group kills the potency of the inhibitor for wild type kinases. Successful complementary design, therefore, leads to favorable binding interactions that are only possible in the engineered kinase/inhibitor complex. Transfection of cells with the gene encoding the engineered kinase generates a cell in which only one kinase can be blocked by the designed inhibitor (see Fig 14).

Importantly, since the mutant kinase serves the same function as the wild-type kinase, an inhibitor of the mutant will affect cell signaling in the same manner as a selective inhibitor of the wild-type kinase in non-transfected cells. The ability to observe the phenotype of cells after selective inhibition of any protein kinase provides a rapid method for determining the unique roles of individual kinases in signal transduction cascades.

We have targeted the src family protein tyrosine kinases for specific inhibitor design because of their ubiquitous importance in mediating cell function . Despite intense investigation, the roles of individual src family members have been difficult to assess because of cellular co-localization and their high sequence identities. Although some potent inhibitors of src family kinases are known , no molecules which can effectively discriminate ((20 fold selectivity for one src family member) between these closely related enzymes have been identified .

Two functionally important src kinases, v-Src and Fyn, were chosen as the primary targets of our mutant kinase/inhibitor pair design. Src kinase has emerged as a leading drug target because of its implication in the oncogenesis of breast, lung, and colon cancers. Although v-Src is the prototype for oncogenic tyrosine kinases, no small molecule inhibitors which are highly selective for this kinase have been discovered. Fyn is a src family tyrosine kinase which is important in T cell receptor mediated lymphocyte activation. Src and Fyn share a similar domain structure and have approximately 85% amino acid identity in their catalytic domains. The close structural relationship of the src family members provides the ideal test of our ability to engineer enzyme/inhibitor specificity between highly homologous kinases. If one can discriminate between these closely related src members using a cell permeable inhibitor, it is likely that specificity for members of other protein kinase families can also be achieved using a similar approach.

## Results and Discussion

### Enzyme engineering

From our previous efforts to engineer kinases with novel ATP specificity, we identified a functionally conserved residue in the ATP binding pocket of v-Src (Ile 338) which could be mutated to glycine without altering the phosphoacceptor specificity or biological function of the kinase. The space creating mutation causes only a modest drop in  $k_{cat}$ , a modest increase in the  $K_m$  for ATP and no quantitative change in the level of fibroblast transformation (Shah K, unpublished results). The biological substrates of the mutant v-Src are unchanged and I338G v-Src carries out the same biological functions as wild type v-Src. All crystal structures of ATP bound protein kinases have revealed a close contact interaction between the residue corresponding to 338 (Src numbering) and ATP. Analysis of protein kinase sequence alignments confirmed that residue 338 contains a bulky side chain (usually Thr, Ile, Leu, Met, or Phe) in all known eukaryotic protein kinases. Thus, a glycine mutation at the 338 position should create a novel pocket that is not present in any wild type kinase. Due to the expanded ATP binding site, the glycine mutant kinases should

accept bulky inhibitors that could not bind wild type kinases. Using standard methods we cloned, expressed and purified the glutathione-S-transferase (GST) fusion protein of the WT and I338G v-Src catalytic domains as described previously . WT Fyn, T339G Fyn (Src numbering), and WT Abl were also expressed and purified as GST fusion proteins.

#### Inhibitor design and synthesis

To test our basic design strategy we screened the WT and I338G v-Src SH1 domains against a previously synthesized panel of N-6 substituted adenosine molecules for selective inhibition of I338G v-Src over WT v-Src. Because adenosine is only a moderate inhibitor of src family tyrosine kinases, we did not expect to discover a potent inhibitor of the engineered kinase. As expected, all of the N-6 adenosine analogues inhibited I338G v-Src more potently than WT v-Src (data not shown). The most potent inhibitor found in this screen was N-6 cyclopentyloxyadenosine (1, Fig 15a.) with a 50% inhibitory concentration ( $IC_{50}$ ) of 1 mM for I338G v-Src.

Subsequent experiments to test for selectivity demonstrated that N-6 cyclopentyloxyadenosine showed no detectable *in vitro* inhibition of WT v-Src or Fyn at concentrations up to 400 mM. This first screen encouraged us to pursue the strategy of developing novel inhibitors of I338G v-Src since our design had allowed us to readily overcome selectivity barriers which are major problems in conventional inhibitor discovery.

As inhibitors, adenosine analogues are not ideal because of the many cellular functions performed by adenosine as well as the large number of cellular proteins which bind adenosine. N-6 adenosine analogues have been shown to act as adenosine receptor agonists and antagonists , and one can imagine N-6 adenosine analogues acting as substrates for nucleoside kinases. For these reasons we turned to a class of known tyrosine kinase inhibitors that are not direct analogues of biologically known molecules. Our design strategy called for a core structure which exhibits potent inhibition of multiple wild type kinases and is easily synthesized. Also, the binding

orientation of the molecule in the enzyme active site must be known or readily predictable. In addition, the molecule must bind in a manner in which the site pointing toward Ile338 can be easily modified. As our core inhibitor structure we chose 4-amino-1-*tert*-butyl-3-phenylpyrazolo [3,4-*d*]pyrimidine (**2**, Fig 15b.). This molecule is a derivative of

4-amino-1-*tert*-butyl-3-(*p*-methylphenyl)pyrazolo[3,4-*d*]pyrimidine (PP1) which was reported by Hanke and co-workers as a potent src family kinase inhibitor . Based on the co-crystal structure of the src family kinase, Hck, bound to the general kinase inhibitor, quercetin (**5**, Fig 16), we postulated that **2** binds to src family kinases in a conformation similar to that of ATP. The predicted binding orientation of **2** in Hck is shown in an overlay with the known Hck co-crystal structures of AMP PNP (**6**) and quercetin (Fig 16b.) . In this conformation the easily derivatizable N-4 position of **2** corresponds to the N-6 of ATP (close contact with residue 338, Fig 16c.) and the *tert*-butyl moiety roughly corresponds to the ribose ring of ATP. We further hypothesized that in this orientation, the C-3 phenyl ring of **2** could bind in a pocket that surrounds the N-7 of ATP as seen in the Hck/quercetin co-crystal structure . This analysis lead us to synthesize a small panel of N-4 derivatized analogues of **2** (Fig 2).

#### Identification of a uniquely selective inhibitor

The panel of pyrazolo[3,4-*d*]pyrimidines was screened against WT and I338G v-Src kinases (see FIG 13). All of the analogues are better inhibitors of the engineered v-Src as compared to wild type, confirming our prediction of the binding orientation of **2** in the kinase active site. Any derivatization of **2** at the N-4 position destroys the inhibitory activity against WT v-Src (no detectable inhibition at the limit of solubility, 300 mM). All 10 analogues demonstrated measurable inhibition of I338G v-Src and several of the compounds have IC<sub>50</sub>'s in the low mM range. The N-4-(*p*-*tert*-butyl)benzoyl analogue (**3g**) is the most potent inhibitor of I338G v-Src in the panel (IC<sub>50</sub> = 430 nM). This molecule shows no inhibition of WT v-Src at 300 mM suggesting that **3g** is at least a 1000 fold better inhibitor of the mutant v-Src as

compared to wild type. The large size of the derivatization needed to achieve sub-micromolar potency for the I338G v-Src active site was rather unexpected. We removed only four carbon atoms from the ATP binding site and derivatized the parent molecule with eleven carbon atoms. This discrepancy may be due to an imperfection in our binding prediction. Also the Ile to Gly mutation may confer greater flexibility to the enzyme active site allowing the mutant kinase to accept a larger inhibitor analogue than predicted. To confirm that 3g does inhibit I338G v-src at the ATP binding site we investigated its kinetics of inhibition at various ATP concentrations. Lineweaver-Burk analysis confirmed that 3g does inhibit I338G v-Src competitively with respect to ATP with an inhibitory constant ( $K_i$ ) of approximately 400 nM (data not shown).

The panel of inhibitor analogues was next screened against WT Fyn to investigate their potential to cross react with this kinase. WT Fyn was chosen as the “worst case” control of wild type kinases because the published parent molecule, PP1, and 2 are highly potent (low nM) Fyn inhibitors. Many of the 10 synthetic analogues did not display high selectivity for the target kinase (see FIG 13). The N-acyl analogues with saturated ring systems (3a-3c) effectively inhibit wild type Fyn. The N-methylene compounds (4b, 4d, 4e) are sufficiently orthogonal to WT Fyn but show only poor to moderate inhibition of the engineered v-Src. Importantly, 3g, the most potent inhibitor of the mutant v-Src inhibited WT Fyn very weakly ( $IC_{50}$ = 300 mM). Thus, 3g inhibits the engineered v-Src over 700 times more effectively than WT Fyn, which is likely to be the wild type cellular kinase which is most capable of binding the molecule.

We also tested whether other non-src family kinases were fortuitously inhibited by 3g *in vitro*. The serine/threonine kinases, PKCd and PKA, were not detectably inhibited at concentrations up to 300 mM. Likewise, 3g exhibited only weak inhibition ( $IC_{50}$ >300 mM) of the Abl tyrosine kinase. Therefore 3g satisfied all of our initial design requirements for potent selective inhibition of one engineered kinase.



### Selectivity in whole cells

To further demonstrate that **3g** does not inhibit wild type tyrosine kinases we investigated the effects of **3g** treatment on the B cell receptor (BCR) mediated phosphorylation cascade. Src family (Fyn, Lyn, Lck, Blk) and non-src family tyrosine kinases (Btk, Syk) are known to be activated upon BCR cross-linking. Due to the amplifying nature of the BCR mediated cascade, inhibition of any of these kinases would dramatically alter the distribution and intensity of post-activation cellular phosphotyrosine. Because **3g** was designed to be sterically incompatible with the active sites of wild type kinases, it should not disrupt tyrosine phosphorylation dependent signaling in wild type B cells. Figure 17 (lane 3) demonstrates that 100 mM **3g** treatment of antigen receptor cross linked murine B cells has no effect on the phosphotyrosine pattern of B cell stimulation (compare to lane 2). The signal intensities of all the major bands are unchanged and only slight depletion of some minor bands is detectable, confirming that **3g** does not appreciably inhibit the panel of tyrosine kinases that are activated by BCR cross linking. Treatment of B cells with 100 mM **2**, however, causes a significant reduction in tyrosine phosphorylation (Fig 4, lane 4) that is consistent with its potent inhibition of wild type src family kinases.

### Selective inhibition of I338G v-Src in NIH3T3 cells

In order to use our selective inhibitor to study a Src mediated pathway we retrovirally introduced both WT and I338G v-Src into NIH3T3 fibroblasts. These cells acquire a transformed phenotype which is dependent on v-Src expression. We sought to show that **3g** could selectively disturb the Src dependent signal transduction pathway of I338G v-Src transformed cells while not affecting WT transformed cells. Treatment of WT v-Src infected cells (100 mM **3g**) causes no loss of tyrosine phosphorylation compared to control DMSO treated lanes (Fig 18), demonstrating that the designed inhibitor does not inhibit WT v-Src or any of the other tyrosine kinases that are activated by v-Src mediated cellular transformation. Equivalent treatment of I338G v-Src transformed cells gives rise to a dramatic diminution in the tyrosine

phosphorylation of the putative v-Src substrate, p36, as well as a moderate overall decrease in the cellular level of phosphotyrosine. Previously, it has been shown that treatment of v-Src transformed cells with general tyrosine kinase inhibitors causes a reduction in the tyrosine phosphorylation of a 36kD protein. It is thought that p36 is associated with a specific phosphotyrosine phosphatase, possibly explaining its rapid dephosphorylation in inhibitor treated cells. The 3g IC<sub>50</sub> for p36 phosphotyrosine signal in I338G v-Src expressing cells ((50 mM) is roughly 100 times the *in vitro* value (data not shown). This is presumably due to the fact that the inhibitor must compete with millimolar concentrations of ATP for the kinase active site in the cellular experiments.

#### **Selective inhibition of I338G mutant v-Src reverses transformed cell morphology**

V-Src activity is required for Rous sarcoma virus transformation of mammalian cells. Treatment of the I338G v-Src expressing NIH 3T3 cells with 100 mM 3g caused dramatic changes in cell morphology which are consistent with the reversal of transformation (Fig 19). The mutant cells that were treated with inhibitor 3g appeared flat and did not exhibit growth characteristics of transformed cells (i.e. the ability to grow on top of one another). Under identical conditions, WT v-Src infected cells demonstrated the prototypical rounded morphology and overlapping growth patterns of transformed cells.

To further demonstrate the selective reversal of cell morphology we used fluorescence microscopy to view 3g treated cells after staining the cellular polymerized actin with phalloidin-FITC (Fig 19). Non-transformed NIH3T3 cells show long actin spindles that form across the cells. V-Src transformed cells (both WT and I338G) appear rounded with no discernible pattern of actin formation. In agreement with the light microscopy data, inhibitor treated WT v-Src expressing cells appear indistinguishable from untreated WT cells. However, 3g treated I338G v-Src expressing cells have defined polymerized actin strings, strongly resembling the actin formations of non-transformed NIH3T3 fibroblasts. These inhibitor treated cells have an

exaggerated flattened morphology and show peripheral actin staining that is not present in the non-transformed NIH3T3 cells. This data shows that **3g** can uniquely induce morphological changes in cells which are engineered to contain a single amino acid change in the kinase of interest. This is the first demonstration that a small molecule inhibitor selective for a tyrosine kinase oncogene product can revert the morphological changes associated with cellular transformation. Previous examples of morphological reversion of transformation by herbimycin A (and other benzoquinone ansamycins) have recently been shown to operate via a mechanism unrelated to kinase inhibition consisting of heat shock protein (hsp90) mediated targeting of the oncogenic tyrosine kinase to the proteasome.

#### **Generalization to other kinases**

The advantage of using mutagenesis to provide a unique molecular difference between the enzyme of interest and all others is that, due to the conserved kinase fold, the approach should be extendible across the kinase superfamily. Almost all known protein kinases contain a bulky side chain at the position corresponding to residue 338 of v-Src. Therefore a space creating mutation at this position should render multiple kinases susceptible to selective inhibition. To test this we measured the inhibition of the analogues against T339G Fyn (Table 1). There exists a striking similarity in the structure activity relationships of the analogues for I338G v-Src and T339G Fyn. In agreement with the data for I338G v-Src, **3g** was the most potent inhibitor analogue against T339G Fyn, exhibiting an  $IC_{50}$  of 830 nM. This corresponds to greater than 300 fold selectivity for T339G Fyn over WT Fyn. The implication of this data is that multiple tyrosine kinases can be systematically engineered to preferentially accept one inhibitor analogue without the need to screen large libraries of putative inhibitors.

#### **Conclusion**

In this report we describe a novel approach to selective protein kinase inhibition through the complementary engineering of chemical sensitive kinases and rationally designed inhibitors. We demonstrate that high selectivity for the target kinase can be

achieved in whole cells, and that active site inhibition of an oncogenic tyrosine kinase can be sufficient for the disruption of a transformed cell morphology. Because the approach is easily generalized, it should have far reaching applications in deconvoluting signal transduction pathways as well as validation of kinases as targets for drug design. The pace of effective drug discovery is limited by the identification and validation of important drug targets. This is not a trivial problem in a milieu of 2000 homologous proteins. The use of chemical sensitive mutants of protein kinases expands the capability to probe the cellular and physiological effects of pharmacological kinase inhibition. Since transfected cell lines and even "knock-in" mice can now be generated rapidly, our approach should greatly expedite the process of testing the effects of selective inhibition of a given kinase in a whole cell or animal model. As more inhibitor-bound protein kinase crystal structures become available, this strategy will allow for the systematic investigation of the effects of time and dose dependent inhibition of any given kinase in the scope of an entire signal transduction cascade.

## Materials and methods

### *Chemical synthesis*

All starting materials and synthetic reagents were purchased from Aldrich unless otherwise noted. All compounds were characterized by <sup>1</sup>H NMR and high resolution mass spectrometry. 4-Amino-1-*tert*-butyl- 3-phenylpyrazolo [3,4-*d*] pyrimidine (2) was synthesized according to Hanefeld, *et al.*

**General procedure for N-4 acylation of 2 (3a-3g).** To a solution of 2 ((100 mg) dissolved in 2 mL pyridine was added 10 equivalents of the desired acyl chloride at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 12 hours. The reaction was quenched by the addition of 25 mL water. The resulting mixture was extracted with Et<sub>2</sub>O and the combined Et<sub>2</sub>O extracts were washed with 1N HCl and 5% NaHCO<sub>3</sub>. The Et<sub>2</sub>O layer was dried over MgSO<sub>4</sub> and evaporated. The residue was purified by flash chromatography on 25g silica gel by elution with

1:1 Et<sub>2</sub>O/hexanes to yield pure **3a-3g**.

**4-cyclobutylamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3a):** yield 0.0116 g (16%), white powder; HRMS (EI) molecular ion calcd. for C<sub>20</sub>H<sub>23</sub>N<sub>5</sub>O 349.19049, found 349.18762; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, ppm) δ 1.86 (9H, s), 1.89-2.27 (6H, m), 3.58 (1H, m), 7.26-7.67 (5H, m), 8.69 (1H, s).

**4-cyclopentylamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3b):** yield 0.0456 g (68%), white powder; HRMS (EI) molecular ion calcd. for C<sub>21</sub>H<sub>25</sub>N<sub>5</sub>O 363.20615, found 363.20398; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.41-1.91 (8H, m), 1.87 (9H, s), 2.97 (1H, m), 7.51-7.67 (5H, m), 8.70 (1H, s).

**4-cyclohexylamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3c):** yield 0.0575 g (84%), white powder; HRMS (EI) molecular ion calcd. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.21-1.93 (10H, m), 1.86 (9H, s), 2.43 (1H, m), 7.51-7.67 (5H, m), 8.70 (1H, s).

**4-2'-furylamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3d):** yield 0.0342 g (60%), white powder; HRMS (EI) molecular ion calcd. for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> 361.15407, found 361.15254; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.87 (9H, s), 6.52 (1H, d), 7.23 (1H, d), 7.43-7.53 (5H, m), 7.95 (1H, s), 8.59 (1H, s).

**4-benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3e):** yield 0.1309 g (56%), white powder; HRMS (EI) molecular ion calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O 371.17933, found 371.17324; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.41-1.91 (8H, m), 7.22-8.11 (10H, m), 8.48 (1H, s).

**4-(p-methyl)benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (3f):** yield 0.0751 g (33%), white powder; HRMS (EI) molecular ion calcd. for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O 385.19499, found 385.18751; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.88 (9H, s), 2.42

(3H, s), 7.19 (2H, d), 7.41-8.11 (7H, m), 8.49 (1H, s).

**4-(p-tert-butyl)benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (3g):**  
yield 0.1050 g (42%), white powder; HRMS (EI) molecular ion calcd. for  $C_{26}H_{29}N_5O$   
427.23747, found 427.23474;  $^1H$  NMR (270 MHz,  $CDCl_3$ , ppm)  $\delta$  1.35 (9H, s), 1.88  
(9H, s), 7.38-7.99 (9H, m), 8.50 (1H, s).

**General procedure for the reduction of N-4 acyl compounds to N-4 methylene compounds (4b, 4d, 4e).** A round bottom flask was charged with (30 mg  $LiAlH_4$ . The flask was equipped with a pressure equalizing dropping funnel and flushed with dry argon. The  $LiAlH_4$  was suspended in 3 mL THF over an ice bath. Approximately 100 mg of the corresponding N-4 acyl 2 analogue was dissolved in 5 mL THF and added dropwise to the suspension of  $LiAlH_4$ . The reaction mixture was stirred for 30 min on the ice bath and subsequently heated to reflux for 30 min. The reaction was quenched by the sequential, dropwise additions of 1 mL EtOAc, 1 mL water, and 1 mL 6N NaOH. After stirring for five minutes, the reaction mixture was filtered through a celite pad, diluted with water and extracted with  $Et_2O$ . The  $Et_2O$  extracts were combined, dried over  $MgSO_4$ , and evaporated. The residue was purified by flash chromatography on 10 g silica gel by elution with 4:1 hexanes/EtOAc.

**4-cyclopentylmethylamino-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (4b):**  
yield 0.0649 g (75%), clear oil; HRMS (EI) molecular ion calcd. for  $C_{21}H_{27}N_5$   
349.22691, found 349.22420;  $^1H$  NMR (270 MHz,  $CDCl_3$ , ppm)  $\delta$  1.16-2.14 (9H, m),  
1.84 (9H, s), 3.54 (2H, d), 5.51 (1H, s), 7.46-7.67 (5H, m), 8.43 (1H, s).

**4-2'-furylmethylamino-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (4d):** yield  
0.0620 g (66%), beige powder; HRMS (EI) molecular ion calcd. for  $C_{20}H_{21}N_5O$   
347.17483, found 347.17330;  $^1H$  NMR (270 MHz,  $CDCl_3$ , ppm)  $\delta$  1.83 (9H, s), 4.75  
(2H, d), 5.64 (1H, s), 6.25 (2H, d), 7.34-7.63 (6H, m), 8.45 (1H, s).

**4-benzylamino-1-tert-butyl-3-phenylpyrazolo[3,4-*d*]pyrimidine (4e):** yield 0.0520 g (54%), white powder; HRMS (EI) molecular ion calcd. for C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>, 357.19559, found 357.19303; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>, ppm) δ 1.82 (9H, s), 4.76 (2H, d), 5.63 (1H, s), 7.28-7.63 (10H, m), 8.44 (1H, s).

5      *Protein Expression and Purification.*

Site directed mutagenesis and cloning of the genes for the glutathione-S-transferase fusion proteins of WT v-Src SH1 domain, I338G v-Src SH1, WT Fyn, T339G Fyn, and WT Abl into the pGEX-KT plasmid was carried out as described previously . These kinases were expressed in DH5a *E. Coli* and purified on immobilized glutathione beads (Sigma). PKA was purchased (Pierce) and used without further purification. PKCd was expressed as the 6-His construct using the Bac-to-Bac( expression system (pFastBac B vector). PKCd was purified using a QIAexpress( Ni-NTA agarose column.

15      *In Vitro Kinase Inhibition Assay*

IC<sub>50</sub>'s for putative kinase inhibitors were determined by measuring the counts per minute (cpm) of <sup>32</sup>P transferred to an optimized peptide substrate for src family kinases (IYGEFKKK). Various concentrations of inhibitor were incubated with 50 mM Tris (pH 8.0), 10 mM MgCl<sub>2</sub>, 1.6 mM glutathione, 1mg/mL BSA, 133 mM IYGEFKKK, 3.3% DMSO, 0.05 mM kinase and 11 nM (2 mCi) [γ-<sup>32</sup>P]ATP (6000 Ci/mmol, NEN) in a total volume of 30 mL for 30 minutes. Reaction mixtures (25 mL) were spotted onto a phosphocellulose disk, immersed in 10% HOAc, and washed with 0.5% H<sub>3</sub>PO<sub>4</sub>. The transfer of <sup>32</sup>P was measured by standard scintillation counting. IC<sub>50</sub> was defined to be the concentration of inhibitor at which the cpm was 50% of the control disk. When the IC<sub>50</sub> fell between two measured concentrations it was calculated based on the assumption of an inversely proportional relationship between inhibitor concentration and cpm between the two data points. Because the solubility limit of the inhibitor analogues in aqueous solutions is (300 μM, IC<sub>50</sub> values of (250 μM are approximate as full titrations to the upper limit of inhibition could not

be tested.  $IC_{50}$ 's for non-src family kinases were measured equivalently with the following exceptions. Kemptide (Pierce, 133 mg/mL) was used as the substrate for PKA. An optimized Abl substrate (EAIYAAPFAKKK, 133 mg/mL) was used for Abl assays. PKCd assays were performed in the presence of 17 ng/mL diacyl glycerol (Sigma) and 17 ng/mL phosphatidyl serine (Sigma) with 170 ng/mL histone (Sigma) as the kinase substrate.

#### *Murine B Cell Assay*

Splenic lymphocytes were isolated from 6-20 week old Balb/c or C57/B6 mice. The cells were washed out of the spleen into RPMI media containing 1 mg/mL DNase I and the red blood cells were lysed in 17 mM tris-ammonium chloride, pH 7.2. Approximately  $4 \times 10^6$  cells were incubated at 37°C for 30 minutes with 100 mM of 3g or 2 in 1.1% DMSO. B cell stimulation was initiated by the addition of 2 mg of goat anti-mouse IgM (Jackson Immuno Research, cat# 115-005-075) and subsequent incubation for 5 minutes at 37°C. The cells were isolated by centrifugation (13,000 rpm, 2 min) and lysed (lysis buffer: 1% Triton X-100, 50 mM tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 mM PMSF, 2 mM sodium orthovanadate, 10 mg/mL leupeptin, 10 mg/mL aprotinin). The cellular debris was then pelleted at 13,000 rpm for 15 min. Cellular proteins were separated by 10% polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane by Western blotting. Phosphotyrosine containing proteins were visualized by immunoblotting with anti-phosphotyrosine antibody (Upstate Biotechnology, Inc.).

#### *Retroviral Infection of NIH 3T3 Fibroblasts*

Genes encoding WT and I338G v-Src were transfected into a packaging cell line and NIH 3T3 fibroblasts were retrovirally infected using the pBabe retroviral vector and a puromycin (2.5 mg/mL) selectable marker as described (Shah, K., Liu, Y., Shokat, K.M., in preparation). WT and I338G v-Src transformed cells were cultured in DMEM/10% BCS containing 2.5 mg/mL puromycin.



#### Inhibition of v-Src in NIH3T3 Fibroblasts

Non-transformed NIH3T3 cells, WT v-Src transformed NIH3T3 cells, and I338G v-Src transformed NIH3T3 cells were incubated at 37°C with 1.1% DMSO or 100 mM **3g** in 1.1% DMSO. After 12 hours, the cells were washed with PBS and lysed (lysis buffer: 1% Triton X-100, 50 mM tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 mM phenylmethylsulphonyl fluoride, 2 mM sodium orthovanadate, 10 mg/mL leupeptin, 10 mg/mL aprotinin). The lysate was clarified by centrifugation at 13,000 rpm for 15 min. Lysate protein concentrations were normalized and equal volumes of the lysate were resolved electrophoretically and analyzed for phosphotyrosine content as described above.

#### *Microscopy*

Non-transformed, WT v-Src transformed, and I338G v-Src transformed NIH3T3 fibroblasts were grown in DMEM/10% BCS on tissue culture treated slides. V-Src expressing cells were treated with either 1.1% DMSO or 100 mM **3g** in 1.1% DMSO. After 48 hours cells were photographed at 400( magnification on an Nikon TMS light microscope. Immediately following light microscopy, the cells were fixed for 20 min in 3.7% formaldehyde/PBS and permeabilized for 60 sec in 0.2% Triton X-100/(PBS. Permeabilized cells were incubated with 200 ng/mL phalloidin-FITC/PBS for 20 min. Slides were rinsed with PBS and polymerized actin was visualized by fluorescence microscopy at 600( magnification on a Zeiss fluorescence microscope.

#### **EXAMPLE 6**

##### **Confirming Retention of Protein Substrate Specificity and biological activity**

This could be carried out as described in (79). Further, the stereo typed role of v-Src in the oncogenic transformation of NIH 3T3 cells can be determined by observing the morphological change in cells expressing v-Src. The NIH 3T3 cells expressing mutant I338G v-Src display the identical morphological features of cells expressing wild-type v-Src which are dramatically distinct from NIH 3T3 cells which do not express either v-Src kinase, confirming that the I338G mutation does not lead to any

loss or gain of biological function of normal v-Src. Further, an assay for the ability of NIH 3T3 cells to grow without "contact inhibition" can be measured in a cell culture based assay containing agarose, a viscous growth medium. The wild-type v-Src and mutant v-Src expressing NIH 3T3 cells display the exact same ability to form large growth colonies in this stereotyped assay as well, further confirming their identical functions (including substrate specificity, kinetics, cell distribution, etc.) In fibroblasts.

#### **EXAMPLE 7**

##### **Confirmation that the orthogonal inhibitor does not inhibit wild-type kinases in cells which express multiple tyrosine kinases.**

To confirm our initial assays regarding the orthogonal nature of compound 3 in purified kinases described in Example 2 we conducted inhibition experiments using whole cells (see Fig. 4, two left lanes). Anti-phosphotyrosine blots of pyrazolo pyrimidine (2-6) (25  $\mu$ M) treated NIH 3T3 cells expressing v-Src kinase were performed by lysing cells in modified RIPA buffer according to the method of Coussens et. al. (84). Cells were also treated for various times before lysis and anti-phosphotyrosine detection. Proteins were separated by 12.5% SDS-PAGE and transferred to Protran BA85 (Schleicher-Schuell). The blot was probed with the anti-phosphotyrosine monoclonal antibody 4G10 (gift of Dr. Brian Druker, Oregon Health Sciences Center Portland, Oregon) and the bound antibody was detected via enhanced chemiluminescence (cat. 34080, Pierce) following treatment with HRP-coupled goat-anti-mouse antibody (VWR cat. 7101332) according to the manufacturer's instructions.

#### **EXAMPLE 8**

##### **Identifying the Substrates**

A schematic representation of an experimental approach to identifying v-Src substrates is outlined in FIG. 1 and the data showing experimental validation is in FIG. 4. The assays were performed by making anti-phosphotyrosine blots of pyrazolo

pyrimidine (2-6) (25  $\mu$ M) treated NIH 3T3 cells expressing either v-Src or v-Src (I338G) kinases were performed by lysing cells in modified RIPA buffer according to the method of Coussens et. al. (84). Cells were also treated for various times (in a cell culture  $\text{Co}_2$  incubator) before lysis and anti-phosphotyrosine detection. Proteins were separated by 12.5% SDS-PAGE and transferred to Protran BA85 (Schleicher-Schuell). The blot was probed with the anti-phosphotyrosine monoclonal antibody 4G10 (gift of Dr. Brian Druker, Oregon Health Sciences Center Portland, Oregon) and the bound antibody was detected via enhanced chemiluminescence (cat. 34080), Pierce) following treatment with HRP-coupled goat-anti-mouse antibody (VWR cat. 7101332) according to the manufacturer's instructions. As discussed in Example 7, the two left lanes in FIG. 4 show the same phosphoprotein band pattern indicating that the orthogonal inhibitor 3 does not inhibit wild type v-Src kinase. The series of lanes in the right gel show a prominent band in the bottom of the gel (corresponding to protein molecular weight 3 kilodaltons) which is lost after treatment with 100  $\mu$ M of compound 3. This specific inhibition of one phosphoprotein is a hallmark of a specific kinase inhibitor. The specificity of the inhibition is confirmed in the last lanes of the gel where the inhibitor is diluted and the phosphorylation of the 36 kilodalton band reappears when the inhibitor concentration is lower than 5  $\mu$ M (the measured  $\text{IC}_{50}$  in vitro is 5  $\mu$ M, see text). This protein has been tentatively identified based on its unique molecular weight, as a protein called annexin II, an actin binding protein, of unknown function.

1. Mustelin, T. 1994. T Cell antigen receptor signaling: Three families of tyrosine kinases and a phosphatase. *Immunity*. **1**: p. 351-356.
2. Renshaw, M.W., E.T. Kipreos, M.R. Albrecht, and J.Y.J. Wang 1992. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. *EMBO J.* **11**(11): p. 3941-3951.
3. Cohen, G.B., R. Ren, and D. Baltimore 1995. Modular Binding Domains in Signal Transduction Proteins. *Cell*. **80**: p. 237-248.
4. Hunter, T. 1987. A Thousand and One Protein Kinases. *Cell*. **50**: p. 823-829.
5. Eiseman, E. and J.B. Bolen 1992. Engagement of the high-affinity IgE receptor activates src protein-related tyrosine kinases. *Nature*. **355**.
6. Murray, A.W. 1994. Cyclin-dependent kinases: regulators of the cell cycle and more. *Chem. and Bio.* **1**(4): p. 191-195.
7. White, M.F. 1991. Mini-Review: Structure and Function of Tyrosine Kinase Receptors. *J. Bioenergetics Biomem.* **23**(1): p. 63-83.
8. Hunter, T. 1995. Protein Kinases and Phosphatases: The Yin and Yang of Protein Phosphorylation and Signaling. *Cell*. **80**: p. 225-236.
9. Sawyers, C.L. 1992. The bcr-abl gene in chronic myelogenous leudaemia. *Cancer Surveys*. **15**: p. 37-51.
10. Crabtree, G.R. and N.A. Clipstone 1994. Signal Transmission between the plasma membrane and nucleus of T lymphocytes. *Annu. Rev. Biochem.* **63**: p. 1045-1083.

11. Kurzrock, R., J.U. Gutterman, and M. Talpaz 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. *New Engl. J. Med.* **319**(15): p. 990-998.

5

12. Ullrich, A. and J. Schlessinger 1990. Signal transduction by receptors with tyrosine kinase activity. *Cell.* **61**: p. 203-212.

10

13. Bolen, J.B., R.B. Rowley, C. Spana, and A.Y. Tsygankov 1992. The Src family of tyrosine protein kinases in hemopoietic signal transduction. *FASEB.* **6**: p. 3403-3409.

15

14. Cicchetti, P., B.J. Mayer, G. Thiel, and D. Baltimore 1992. Identification of a Protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. *Science.* **257**: p. 803-806.

20

15. Sawyers, C.L., J. McLaughlin, A. Goga, M. Havlik, and O. Witte 1994. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. *Cell.* **77**: p. 121-131.

16. Kipreos, E.T. and J.Y.J. Wang 1992. Cell Cycle-regulated binding of c-abl Tyrosine kinase to DNA. *Science.* **256**: p. 382-385.

25

17. Velazquez, L., M. Fellous, G.R. Stark, and S. Pellegrini 1992. *Cell.* **70**: p. 313-320.

18. Duyster, J., R. Baskaran, and J.Y.J. Wang 1995. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. *Proc. Natl. Acad. Sci.,*

USA. 92: p. 1555-1559.

19. Mayer, B.J., P.K. Jackson, and D. Baltimore 1991. The noncatalytic src  
homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated  
cellular proteins with high affinity. *Proc. Natl. Acad. Sci., USA.* 88: p. 627-631.

20. Kamps, M.P., J.E. Buss, and B.M. Sefton 1986. Rous Sarcoma Virus  
Transforming protein lacking myristic acid phosphorylates known polypeptide  
substrates without inducing transformation. *Cell.* 45: p. 105-112.

21. Muller, A.J., A.-M. Pendergast, K. Parmar, M.H. Havlik, N. Rosenberg, and  
O.N. Witte 1993. En Bloc substitution of the Src homology region 2 domain  
activates the transforming potential of the c-abl protein tyrosine kinase. *Proc. Natl.  
Acad. Sci., USA.* 90: p. 3457-3461.

22. Mayer, B.J. and D. Baltimore 1994. Mutagenic analysis of the roles of SH2  
and SH3 domains in regulation of the abl tyrosine kinase. *Mol. Cell. Bio.* 14(5): p.  
2883.

23. Mayer, B.J., P.K. Jackson, R.A. Van Etten, and D. Baltimore 1992. Point  
Mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in  
vitro and transforming activity in vivo. *Mol. Cell. Bio.* 12(2): p. 609-618.

24. Koyama, S., H. Yu, D.C. Dalgarno, T.B. Shin, L.D. Zydowsky, and S.L.  
Schreiber 1993. Structure of the PI3K SH3 domain and analysis of the SH3 Family.  
*Cell.* 72: p. 945-952.

25. Yu, H., M.K. Rosen, T.B. Shin, C. Seidel-Dugan, J.S. Brugge, and S.L.  
Schreiber 1992. Solution Structure of the SH3 domain of Src and identification of its

ligand-binding site. *Science*. **258**: p. 1665-1668.

26. Kohda, D., H. Hatanaka, M. Odaka, V. Mandiyan, A. Ullrich, J. Schlessinger, and F. Inagaki 1993. Solution Structure of the SH3 domain of phospholipase C-gamma. *Cell*. **72**: p. 953-960.

27. Waksman, G., S.E. Shoelson, N. Pant, D. Cowburn, and J. Kuriyan 1993. Crystal structure/NMR of SH2. *Cell*. **72**: p. 779-790.

28. Eck, M.J., S.E. Shoelson, and S.C. Harrison 1993. SH2 crystal structure. *Nature*. **362**: p. 87.

29. Wang, J.Y.J., C. Queen, and D. Baltimore 1982. Expression of an Abelson Murine Leukemia Virus-encoded protein in *Escherichia coli* Causes Extensive Phosphorylation of Tyrosine Residues. *J. Biol. Chem.* **257**(22): p. 13181-13184.

30. Schwartzerg, P.L., A.M. Stall, J.D. Hardin, K.S. Bowdish, T. Humaran, S. Boast, M.L. Harbison, E.J. Robertson, and S.P. Goff 1991. Mice homozygous for the abl mu mutation show poor viability and depletion of selected B and T cell populations. *Cell*. **65**: p. 1165-1175.

31. Tybulewicz, V.L., C.E. Crawford, P.K. Jackson, R.T. Bronson, and R.C. Mulligan 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. *Cell*. **65**: p. 1153-1163.

32. Brugge, J.S. & Erikson, R.L. 1977. *Nature* **269**(5626), 346-8.

33. Jove, R. & Hanafusa, H. 1987. *Ann. Rev. Cell Biol.* **3**, 31-56.

34. Erpel, T. & Courtneidge, S.A. 1995. *Curr. Op. in Cell Biology* **7**, 176-

182.

35. Pawson, T. 1995. *Nature* **373**, 573-580.

5 36. Waksman, G., Kominos, D., Robertson, S.C., Pant, N., Baltimore, D.,  
Birge, R.B., Cowburn, D., Hanafusa, H., Mayer, B.J., Overduin, M., Resh, M.D.,  
Rios, C.B., Silverman, L. & Kuriyan, J. 1992). *Nature* **358**, 646-653.

37. Taylor, S.J. & Shalloway, D. 1993. *Curr. Opin. Genet. Dev.* **3**, 26-34.

10 38. Brown, M.T. & Cooper, J.A. 1996. *Biochemica et Biophysica Acta*  
**1287**, 121-149.

15 39. Songyang, Z., Carraway, K.L.I., Eck, M.J., Harrison, S.C., Feldman,  
R.A., Mohammadi, M., Schlessinger, J., Hubbard, S.R., Smith, D.P., Eng, C.,  
Lorenzo, M.J., Ponder, B.A.J., Mayer, B.J. & Cantley, L.C. 1995. *Nature* **373**, 536-  
539.

40. Kamps, M.P. & Sefton, B.M. 1988. *Oncogene Res.* **3**, 105-115.

20 41. Weijland, A. & Parmeggiani, A. 1993. *Science* **259**, 1311-1314.

42. Belshaw, P.J., Schoepfer, J.G., Liu, K.-Q., Morrison, K.L. & Schreiber, S.L.  
1995. *Angew. Chem. Int. Ed. Engl.* **34**(19), 2129-2132.

25 43. Fujii, T., Wu, C.C., Itaya, T., Moro, S. & Saito, T. 1973. *Chem. Pharm. Bull.*  
**21**(8), 1676-1682.

44. Robins, M.J. & Trip, E.M. 1973. *Biochemistry* **12**(12), 2179-2187.



45. McLaughlin, L.W., Piel, N. & Hellmann, T. 1985. *Synthesis*, 322-3.
46. Kikugawa, K., Iizuka, K. & Ichino, M. 1973. *J. Med. Chem.* **16**, 358-364.
- 5 47. Ludwig, J. 1981. *Acta Biochim. et Biophys. Acad. Sci. Hung.* **16**(304), 131-133.
48. Hecht, S.M. & Kozarich, J.W. 1973. *Biochim. Biophys. Acta* **331**, 307-309.
- 10 49. Reikofski, J. & Tao, B.Y. 1992. *Biotech. Adv.* **10**, 535-554.
50. Xu, B., Bird, G.V. & Miller, T.W. 1995. *J. Biol. Chem.* **270**, 29825-29830.
51. Fukazawa, H., Li, P., Mizuno, S. & Uehara, Y. 1993. *Analytical Biochemistry*,  
15 **212**, 106-110.
52. Lee, T.R., Niu, J. & Lawrence, D.S. 1995. *J. Biol. Chem.* **270**(10), 5375-5380.
53. Kwiatkowski, A.P. & King, M.M. 1987. *Biochemistry* **26**, 7636-7640.
- 20 54. Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. (1994) *Nature* **372**, 746-754.
55. Mohammadi, M., Schlessinger, J. & Hubbard, S.R. 1996. *Cell* **86**, 577-587.
- 25 56. Zheng, J., Knighton, D.R., Ten Eyck, L.F., Karlsson, R., Zuong, N.-H., Taylor, S.S. & Sowadski, J.M. 1993. *Biochemistry* **32**, 2154-2161.
57. Jeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J. &  
30 Pavletich, N.P. 1995. *Nature* **376**, 313-320.

58. Kamps, M.P., Taylor, S.S. & Sefton, B.M. 1984). *Nature* **310**, 589-592.
59. Zoller, M.J., Nelson, N.C. & Taylor, S.S. 1981. *J. Biol. Chem.* **256**, 10837-10842.
60. Taylor, S.S. & Radzio-Andzelm, E. 1995. *Structure* **2**, 345-355.
61. DeClue, J.E. & Martin, G.S. 1989. *J. Virol.* **63**(2), 542-554.
62. Seidel-Dugan, C., Meyer, B.E., Thomas, S.M. & Brugge, J.S. 1992. *Mol. Cell Biol.* **12**(4), 1835-45.
63. Czernilofsky, A.D., Levison, A.D., Varmus, H.E., Bishop, J.M., Tischler, E. & Goodman, H.M. 1980. *Nature (London)* **287**, 198-200.
64. Fersht, A., *Enzyme Structure and Mechanism*. Second ed. 1985, New York: W.H. Freeman and Co. 475.
65. Hunter, T. & Sefton, B.M. 1980. *Proc. Natl. Acad. Sci. USA* **77**(3), 1311-1315.
66. Ozawa, K., Szallasi, Z., Kazanietz, M.G., Blumberg, P.M., Mischak, H., Mushinski, J.F. & Beaven, M.A. 1993. *J. Biol. Chem.* **268**(3), 1749-1756.
67. Schultz, C., Vajanaphanich, M., Genieser, H.-G., Jastorff, B., Barret, K.E. & Tsien, R.Y. 1994. *Mol. Pharm.* **46**, 702-708.
68. Merritt, E.A. & Murphy, M.E.P. 1994. *Acta Cryst.* **D50**, 869-873.
69. Bacon, D.J. & Anderson, W.F. 1988. *J. Molec. Graphics* **6**, 219-220.

70. Schluckebeir, G., O-Gara, M., Saenger, W., & Chen, X. "Universal Catalytic Domain Structure of AdoMet-dependent Methyltransferases," 1995. *Mol. Biol.* **247** pg 16-20.

5

71. *Protein Kinase Facts Book*, G. Hardie and S. Hanks, Eds. 1995. Academic Press, San Diego, ISBN 0-12-324719-5.

10

72. *Principles of Biochemistry*, A. Lehninger, D. Nelson and M. Cox, 2nd Ed., 1993. Worth Publishers, New York, ISBN 0-87901-500-4.

73. C. R. Faltynek, et al. 1995. *Biochemistry* **34**, 12404-10.

74. J. Hanke, et al. 1996. *J. Biol. Chem.* **271**, 695-701.

15

75. B. J. Druker, et al. 1996. *Nat. Med.* **5**, 561-6.

20

76. U. Hanefeld, C. W. Rees, A. J. P. White, D. J. Williams (1996). One-pot synthesis of tetrasubstituted pyrazoles-proof of regiochemistry *J. Chem. Soc. Perkin Trans I* , 1545-1552.

77. J. Reikofski, B. Y. Tao (1992). Polymerase Chain Reaction(PCR Techniques for Site-directed Mutagenesis *Biotech. Adv.* **10**, 535-554.

25

78. B. Xu, G. V. Bird, T. W. Miller (1995). Substrate Specificities of the Insulin and Insulin-like Growth Factor 1 Receptor Tyrosine Kinase Catalytic Domains *J. Biol. Chem.* **270**, 29825-29830.

79. K. Shah, Y. Liu, C. Deirmengian, K. M. Shokat (1997). Engineering Unnatural Nucleotide Specificity for Rous sarcoma virus tyrosine kinase to Uniquely

Label its Direct Substrates *Proc. Natl. Acad. Sci* **94**, 3565-3570.

80. J. P. Morgenstern, H. Land (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line *Nucleic Acids Res.* **18**, 3587-3596.

5 81. W. S. Pear, G. P. Nolan, M. L. Scott, D. Baltimore (1993). Production of high-titer helper-free retroviruses by transient transfection *Proc. Natl. Acad. Sci. USA* **90**, 8392-8396.

10 82. O. Danos, R. C. Mulligan (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. *Proc Natl Acad Sci U S A* **85**, 6460-4.

83. T. R. Lee, J. Niu, D. S. Lawrence (1995). The extraordinary active site substrate specificity of pp60c-src. A multiple specificity protein kinase. *J. Biol. Chem.* **270**, 5375-5380.

15 84. P. M. Coussens, J. A. Cooper, T. Hunter, D. Shalloway (1985). Restriction of the In Vitro and In Vivo Tyrosine Kinase Activities of pp60c-src Relative to pp60v-Src *Molecular and Cell. Biol.*, 2753-2763.

20 This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: SHOKAT, KEVAN

5 (ii) TITLE OF INVENTION: ENGINEERED KINASES AND OTHER ENGINEERED  
MULTI-SUBSTRATE ENZYMES, AND METHODS FOR THEIR SYNTHESIS  
AND USE

(iii) NUMBER OF SEQUENCES: 9

## (iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: Klauber & Jackson  
(B) STREET: 411 Hackensack Avenue, 4th Floor  
(C) CITY: Hackensack  
(D) STATE: New Jersey  
15 (E) COUNTRY: USA  
(F) ZIP: 07601

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
20 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US  
(B) FILING DATE:  
(C) CLASSIFICATION:

25 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Jackson Esq., David A.  
(B) REGISTRATION NUMBER: 26,742  
(C) REFERENCE/DOCKET NUMBER: 2275-1-004

30 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 201-487-5800  
(B) TELEFAX: 201-343-1684  
(C) TELEX: 133521

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 27 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: not relevant  
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

40 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Asn Phe Pro Phe Leu Val Lys Leu Glu Phe Ser Phe Lys Asp Asn Ser  
1 5 10 15

Asn Leu Tyr Met Val Met Glu Tyr Val Pro Gly  
20 25

10 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

15 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

20 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn His Pro Asn Ile Val Lys Leu Leu Asp Val Ile His Thr Glu Asn  
1 5 10 15

25 Lys Leu Tyr Leu Val Phe Glu Phe Leu His Gln  
20 25

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

30 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

89

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Rous sarcoma virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Arg His Glu Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu Pro  
1 5 10 15

Ile Tyr Ile Val Ile Glu Tyr Met Ser Lys  
20 25

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Rous sarcoma virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTTGGATCCA TGGGGAGTAG CAAGAGCAAG

30

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

SUBSTITUTE SHEET (RULE 26)

90

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Rous sarcoma virus

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTGAATTCC TACTCAGCGA CCTCCAACAC 30

5

- (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: other nucleic acid

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: YES

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Rous sarcoma virus

15

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGAGAAGCTG GCTCAACTGT ACGCAG 26

- (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20

- (ii) MOLECULE TYPE: other nucleic acid

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: YES

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Rous sarcoma virus

25

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTGCGTACAG TTGAGCCAGC TTCTCA 26

30

- (2) INFORMATION FOR SEQ ID NO:8:

**SUBSTITUTE SHEET (RULE 26)**



91

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- 10 (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Rous sarcoma virus
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
CTACATCGTC GCTGAGTACA TGAG 24
- (2) INFORMATION FOR SEQ ID NO:9:
- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- 20 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Rous sarcoma virus
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
25 CTCATGTACT CAGCGACGAT GTAG 24

DELETED

**DELETED**

**SUBSTITUTE SHEET (RULE 26)**

**DELETED**

**SUBSTITUTE SHEET (RULE 26)**

95

**DELETED**

**SUBSTITUTE SHEET (RULE 26)**

DELETED

SUBSTITUTE SHEET (RULE 26)

97

**DELETED**

**SUBSTITUTE SHEET (RULE 26)**

98

DELETED

SUBSTITUTE SHEET (RULE 26)



WHAT IS CLAIMED IS:

1. A mutant multi-substrate enzyme which accepts at least one orthogonal substrate analog, whereby catalytic activity results in the combination of all or part of said orthogonal substrate with at least one other substrate of said enzyme.
- 5 2. The mutant enzyme of claim 1 wherein said multi-substrate enzyme is a transferase.
3. The mutant enzyme of claim 1 wherein said multi-substrate enzyme is a signal transduction mediator.
4. A mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate.
- 10 5. The mutant protein kinase of claim 4 wherein said mutant protein kinase binds to the orthogonal nucleotide triphosphate with an affinity which is higher than its affinity for the nucleotide triphosphate which is the primary intracellular phosphate donor substrate for the wild-type protein kinase.
6. The mutant protein kinase of claim 4 wherein said orthogonal nucleotide triphosphate  
15 analog is an orthogonal analog of ATP.
7. The mutant protein kinase of claim 4 wherein said orthogonal nucleotide triphosphate analog is a derivative of ATP having a substituent comprising at least three carbon atoms covalently attached to the N<sup>6</sup> position of said ATP.
8. The mutant protein kinase of claim 7 wherein said orthogonal nucleotide triphosphate  
20 analog is selected from the group consisting of N<sup>6</sup>-(cyclopentyl)ATP, N<sup>6</sup>-(cyclopentyloxy)ATP, N<sup>6</sup>-(cyclohexyl)ATP, N<sup>6</sup>-(cyclohexyloxy)ATP, N<sup>6</sup>-(benzyl)ATP, N<sup>6</sup>-(benzyloxy)ATP, N<sup>6</sup>-(pyrrolidino)ATP, and N<sup>6</sup>-(piperidino)ATP.
9. The mutant protein kinase of claim 4 wherein said orthogonal nucleotide triphosphate

analog is N<sup>6</sup>-(cyclopentyl)ATP.

10. The mutant protein kinase of claim 4 which is a mutant protein tyrosine kinase.

11. The mutant protein kinase of claim 10 which is a mutant of an Src protein tyrosine kinase.

12. The mutant protein kinase of claim 10 which is a mutant of a Rous sarcoma virus Src  
5 protein tyrosine kinase.

13. The mutant protein kinase of claim 4 wherein the amino acid sequence differs from that of the wild type protein kinase in that at least one amino acid at a position homologous to the position selected from the group consisting of v-Src position 323 and v-Src position 338 has been replaced with an amino acid selected from the group consisting of alanine and glycine.

10 14. The mutant protein kinase of claim 4 wherein the amino acid at a position homologous to v-Src position 338 has been replaced with glycine.

15. The mutant protein kinase of claim 4 wherein the amino acid at a position homologous to v-Src position 323 and the amino acid at a position homologous to v-Src position 338 have been replaced with alanine.

15 16. The mutant protein kinase of claim 4 wherein said mutant protein kinase has been expressed as a fusion protein.

17. The mutant protein kinase of claim 16 which has been expressed as fusion protein selected from the group consisting of a glutathione-S-transferase fusion protein and a G-Histidine fusion protein.

20 18. A nucleotide sequence which encodes a mutant multi-substrate enzyme which accepts at least one orthogonal substrate analog, whereby catalytic activity of said enzyme results in the combination of all or part of said orthogonal substrate with at least one other substrate of said

enzyme.

19. A nucleotide sequence which encodes a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate.

20. The nucleotide sequence of claim 19 wherein said nucleotide sequence is selected from the group consisting of mRNA, cDNA, gDNA, mitochondrial DNA, chloroplast DNA, satellite DNA, plasmid DNA, viral RNA, and viral DNA.

21. A method for producing a nucleic acid sequence encoding a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate, comprising the steps of:

- a. identifying, from the crystal structure of an identical or homologous enzyme bound to its phosphate donor substrate, one or more amino acids other than glycine which are close enough to an atom of said bound phosphate donor substrate that they would sterically exclude an orthogonal substituent attached to the corresponding atom in said orthogonal nucleotide triphosphate analog; and
- b. mutating a nucleotide sequence which encodes the wild-type protein kinase such that the nucleotide triplets encoding one or more of the identified amino acids are converted to nucleotide triplets that encode amino acids having side chains that are sterically less bulky than the identified amino acids.

22. The method of claim 21 wherein said amino acids of step (a) are within about five angstroms of said atom of said bound phosphate donor substrate.

23. The method of claim 21 wherein said phosphate donor substrate is ATP.

24. The method of claim 23 wherein said atom is the N<sup>6</sup> amino group of ATP.

25. A method for producing a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate, comprising expressing the mutant sequence

of claim 21, whereby said mutant protein kinase is produced.

26. A method for producing a nucleic acid sequence encoding a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate, comprising the steps of:

- 5 a. identifying, from the crystal structure of an identical or homologous enzyme bound to its phosphate donor substrate, one or more amino acids other than glycine which are close enough to an atom of said bound phosphate donor substrate that they would sterically exclude the orthogonal substituent attached to the corresponding atom in said orthogonal nucleotide triphosphate analog;
- 10 b. preparing a plurality of mutant protein kinase-encoding nucleotide sequences having one or more mutations in one or more nucleotide triplets encoding amino acids within ten amino acids of said one or more amino acids, in both the amino terminal and carboxy terminal directions;
- c. expressing said plurality of mutant kinase-encoding nucleotide sequences to produce a
- 15 d. testing said plurality of mutant kinases to select one or more which have the ability to utilize said orthogonal nucleotide triphosphate analog as phosphate donor substrate.

27. A method for producing a mutant protein kinase which accepts an orthogonal nucleotide triphosphate analog as a phosphate donor substrate, comprising expressing one or more mutant

20 sequence of claim 26 found to express such a mutant protein kinase, whereby said mutant protein kinase is produced.

28. A method for producing a nucleic acid sequence encoding a mutant multi-substrate enzyme which accepts at least one orthogonal donor substrate analog, whereby catalytic activity results in the combination of all or part of said orthogonal donor substrate with at least one other,

25 recipient substrate of said enzyme, comprising the steps of:

- a. identifying, from the crystal structure of an identical or homologous enzyme bound to its donor substrate, one or more amino acids other than glycine which are close enough to an atom of said bound donor substrate that they would sterically exclude an orthogonal

substituent attached to the corresponding atom in said orthogonal donor substrate analog;  
and

- b. mutating a nucleotide sequence which encodes the wild-type form of said multi-substrate enzyme such that the nucleotide triplets encoding one or more of the identified amino acids are converted to nucleotide triplets that encode amino acids having side chains that are sterically less bulky than the identified amino acids.

29. The method of claim 28 wherein said amino acids of step (a) are within about five angstroms of said atom of said bound donor substrate.

30. A method for producing a multi-substrate enzyme which accepts at least one orthogonal donor substrate analog, comprising expressing the mutant sequence of claim 28, whereby said mutant multi-substrate enzyme is produced.

31. A method for producing a nucleic acid sequence encoding a mutant multi-substrate enzyme which accepts at least one orthogonal donor substrate analog, whereby catalytic activity results in the combination of all or part of said orthogonal donor substrate with at least one other, recipient substrate of said enzyme, comprising the steps of:

- a. identifying, from the crystal structure of an identical or homologous enzyme bound to its donor substrate, one or more amino acids other than glycine which are close enough to an atom of said bound phosphate donor substrate that they would sterically exclude the orthogonal substituent attached to the corresponding atom in said orthogonal donor substrate analog;
- b. preparing a plurality of mutant multi-substrate enzyme-encoding nucleotide sequences having one or more mutations in one or more nucleotide triplets encoding amino acids within ten amino acids of said one or more amino acids, in both the amino terminal and carboxy terminal directions;
- c. expressing said plurality of mutant multi-substrate enzyme-encoding nucleotide sequences to produce a plurality of mutant multi-substrate enzymes; and

- d. testing said plurality of mutant multi-substrate enzymes to select one or more which have the ability to utilize said orthogonal donor substrate analog as donor substrate.

32. A method for producing a mutant multi-substrate enzyme which accepts at least one orthogonal donor substrate analog as a donor substrate, comprising expressing one or more mutant sequence of claim 31 found to express such a mutant, whereby said mutant multi-substrate enzyme is produced.

33. A method of detecting the one or more intracellular components that are recipient substrates for a multi-substrate enzyme that covalently transfers part or all of a donor substrate to a recipient substrate, comprising:

I. combining:

(a) cells, selected from the group consisting of permeabilized cells, lysed cells, and cells which are naturally permeable to the orthogonal donor substrate analog, which cells express a mutant of said multi-substrate enzyme, which mutant accepts said orthogonal donor substrate analog as a donor substrate; and

(b) said orthogonal substrate analog, having a detectable moiety on the portion thereof that is catalytically transferred to a recipient substrate by said multi-substrate enzyme;

II. incubating said cells under conditions sufficient to allow the mutant multi-substrate enzyme to transfer part or all of the labeled orthogonal donor substrate to the recipient substrate; and

III. detecting the presence or absence of said detectable label on cellular components, whereby the presence of said label on a cellular component indicates that said component is a recipient substrate for said multi-substrate enzyme, and the absence of said label on a cellular component indicates that said component is not a recipient substrate for said multi-substrate enzyme.

34. A method of detecting the one or more intracellular protein substrates for a protein kinase,

comprising:

I. combining:

- (a) cells, selected from the group consisting of permeabilized cells, lysed cells, and cells which are naturally permeable to the orthogonal nucleotide triphosphate substrate analog, which cells express a mutant of said protein kinase, which mutant accepts said orthogonal nucleotide triphosphate analog as a phosphate donor substrate; and
- (b) said orthogonal nucleotide triphosphate analog, having a detectably labeled terminal phosphate;

- II. incubating said cells under conditions sufficient to allow the mutant protein kinase to phosphorylate its one or more protein substrates using said orthogonal nucleotide triphosphate as phosphate donor; and
- III. detecting the presence or absence of said detectably labeled phosphate on cellular proteins, whereby the presence of said label on a cellular protein indicates that said protein is a substrate for said protein kinase, and the absence of said label on a cellular protein indicates that said protein is not a substrate for said protein kinase.

35. The method of claim 34 wherein said mutant binds to said substrate with an affinity that is higher than its affinity for the primary intracellular phosphate donor substrate for the wild-type protein kinase.

36. A method for determining whether a test compound modulates the activity of a multi-substrate enzyme, comprising the steps of:

I. combining:

- (a) cells, selected from the group consisting of permeabilized cells, lysed cells, and cells which are naturally permeable to the orthogonal donor substrate analog, which cells express a mutant of said multi-substrate enzyme, which mutant accepts said orthogonal donor substrate analog as a donor substrate; and
- (b) said orthogonal substrate analog, having a detectable moiety on the portion thereof that is catalytically transferred to a recipient substrate by said multi-substrate

enzyme; and

(c) said test compound;

II. incubating said cells under conditions sufficient to allow the mutant multi-substrate enzyme to transfer part or all of the labeled orthogonal donor substrate to the recipient substrate; and

III. detecting whether there has been an increase or decrease in the presence or absence of said detectable label on cellular components relative to that observed in one or more control experiments where said test compound was omitted, whereby a relative increase in the presence of said label on a cellular component indicates that said test compound has positively modulated the action of said multi-substrate enzyme on that component, and a relative decrease in the presence of said label on a cellular component indicates that said test compound has negatively modulated the action of said multi-substrate enzyme on that component.

37. A method for determining whether a test compound modulates the activity of a protein kinase, comprising the steps of:

I. combining:

(a) cells, selected from the group consisting of permeabilised cells, lysed cells, and cells which are naturally permeable to the orthogonal nucleotide triphosphate substrate analog, which cells express a mutant of said protein kinase, which mutant accepts said orthogonal nucleotide triphosphate analog as a phosphate donor substrate;

(b) said orthogonal nucleotide triphosphate analog, having a detectably labeled terminal phosphate; and

(c) said test compound;

II. incubating said cells under conditions sufficient to allow the mutant protein kinase to phosphorylate its one or more protein substrates using said orthogonal nucleotide triphosphate as phosphate donor; and

III. detecting whether there has been an increase or decrease in the presence or absence of said detectable label on cellular proteins relative to that observed in one or more control experiments where said test compound was omitted, whereby a relative increase in the



presence of said label on a cellular protein indicates that said test compound has positively modulated the action of said protein kinase on that component, and a relative decrease in the presence of said label on a cellular protein indicates that said test compound has negatively modulated the action of said protein kinase on that component.

- 5 38. An inhibitable engineered protein kinase or multi-substrate enzyme selected from kinases prepared in accordance herewith, synthetic analogs thereof, active fragments thereof, congeners thereof, and combinations thereof, for use both diagnostic and therapeutic procedures selected from drug assays, methods of treatment or intervention in disease states such as cancer, HIV or the like.
- 10 39. A transgenic animal that may function as a "knock out" model model for drug screening, wherein the wild-type gene corresponding to a particular kinase associated with a particular disease state is replaced with a gene encoding a mutant kinase, and said screen is used by the interaction of said model with a kinase inhibitor hereof.
- 15 40. A method for the transformation of a target cell in an animal by the preparation of a vector containing DNA molecules that code on expression for a material selected from the group consisting of mutant kinases of Claim 1, kinase inhibitors, agonists and antagonists thereto, active fragments thereof, analogs thereof, degenerate variants thereof, muteins thereof, and combinations thereof.
- 20 41. A drug screen and associate screening method that utilizes an agent selected from the mutant kinase of Claim 1, variants thereof, inhibitors thereof, active fragments thereof, analogs thereof, and combinations thereof.
42. A pharmaceutical composition comprising an active agent selected from a mutant multi-substrate enzyme in accordance with Claim 1, inhibitors thereof, agonists thereof, active

fragments thereof, alleles thereof, analogs thereof, conserved variants thereof, and a pharmaceutically acceptable carrier.

43. Use of the pharmaceutical composition of Claim 41 for the treatment of a disease selected from cancer, HIV, Alshheimers Disease.

2275-1-004 CIP PCT (Sheet 1 of 24)





Figure 1

2275-1-004 CIP PCT (Sheet 2 of 24)



1:	6:	10:
2:	7:	11:
3:	8:	12:
4:	9:	
5:		

Figure 2

2275-1-004 CIP PCT (Sheet 3 of 24)




Figure 3

4/24

2275-1-004 CIP PCT (Sheet 4 of 24)




Figure 4

2275-1-004 CIP PCT

(Sheet 5 of 24)




Figure 5




Figure 6



2275-1-004 CIP PCT

(Sheet 7 of 24)




Figure 7

8/24

2275-1-004 CIP PCT (Sheet 8 of 24)




Figure 8




10/24

2275-1-004 CIP PCT


(Sheet 10 of 24)

## A. Damnacanthal




	IC <sub>50</sub> (μM)
lck	0.10
fyn	2.09
src	0.68
erbB2	3.5

## B. PP1



	IC <sub>50</sub> (μM)
lck	0.005
fyn	0.006
src	0.17
hck	0.020
zap-70	>100
JAK2	>50
EGFR	0.25


## C. CGP 57148




	IC <sub>50</sub> (μM)
bcr-abl	0.025
EGFR	>100
PDGFR	0.030
c-src	>100
c-lyn	>100
PKA	>500
cdc2/cyclin	>100

Figure 10

## A. N-4 Acyl Analogues



## B.

C. *In vitro* Inhibition Data

R' =	IC <sub>50</sub> (μM)		
	WT fyn	WT src	I338G src
H	0.08	35	<1
cyclobutoyl		>>400	12
cyclopentoyl	400	>>400	5
cyclohexoyl	50	>>400	20
benzoyl	>400	>>400	50
2-furoyl		>>400	150

Figure 11

2275-1-004 CIP PCT 12/24 (Sheet 12 of 24)





Figure 12

2275-1-004 CIP PCT (Sheet 13 of 24)

IC<sub>50</sub> (μM)










Molecule	WT XD4	I338G XD4	WT Fyn	T339G Fyn	WT Abl	T120A Abl
	35	0.13	0.05			<<10
		200	>300			
		300	>300			
		>300	>300			
	>300	75	>300	100		>10
	>300	250	>300	26		>10
	>300	85	>300	63		>10
						
						

Figure 13A

2275-1-004 CIP PCT

(Sheet 14 of 24)













						
						
	>300	12	6.5	5		
	>300	19	80	9		
	>300	20	50	5		
	>300	150	15	19		
	>300	10	300	11		(10
	>300	10	300	6		(10
		1.2				<10
		0.63				
		(0.411				1.8
	>300	0.43	300	0.83	300	(10

Figure 13B



2275-1-004 CIP PCT (Sheet 15 of 24)











						
						
						>10
	100	(0.05	0.1			
		>100	>300			
			2			
			7			
						
						
						

Figure 13C

2275-1-004 CIP PCT

(Sheet 16 of 24)











						
						
						
						
						
						
						
						
	>1000	0.510	0.4		<<6.5	
	>300	>10	>300			

Figure 13D

2275-1-004 CIP PCT (Sheet 17 of 24)










	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			

Figure 13E

2275-1-004 CIP PCT

(Sheet 18 of 24)









						
	<10	2.5	<<10			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			
	>300	>10	>300			

Figure 13F

2275-1-004 CIP PCT (Sheet 19 of 24)




Figure 14

2275-1-004 CIP PCT (Sheet 20 of 24)




Figure 15




Figure 16

2275-1-004 CIP PCT

(Sheet 22 of 24)




Figure 17



2275-1-004 CIP PCT (Sheet 23 of 24)




Figure 18

2275-1-004 CIP PCT

(Sheet 24 of 24)




Figure 19



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/52, 9/12, G01N 33/50, A61K 38/45</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/35048</b> <b>(43) International Publication Date:</b> 13 August 1998 (13.08.98)
<b>(21) International Application Number:</b> PCT/US98/02522 <b>(22) International Filing Date:</b> 9 February 1998 (09.02.98) <b>(30) Priority Data:</b> 08/797,522           7 February 1997 (07.02.97)   US 60/046,727        16 May 1997 (16.05.97)   US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</b> US                                   08/797,522 (CIP) Filed on                           7 February 1997 (07.02.97) US                                   60/046,727 (CIP) Filed on                           16 May 1997 (16.05.97) <b>(71) Applicant (for all designated States except US):</b> PRINCETON UNIVERSITY [US/US]; 5 New South Building, P.O. Box 36, Princeton, NJ 08544 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SHOKAT, Kevan, M. [US/US]; 40 Lake Lane, Princeton, NJ 08544 (US). <b>(74) Agents:</b> JACKSON, David, A. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 7 January 1999 (07.01.99)
<b>(54) Title:</b> ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES		
<b>(57) Abstract</b>  <p>Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them. Modified nucleotide triphosphate substrates and methods of making and using them. Methods for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Also engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes. Methods for making and using such engineered enzymes. Modified substrates and methods of making and using them. Methods for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Inter. Appl. No.  
PCT/US 98/02522

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/52 C12N9/12 G01N33/50 A61K38/45

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SHAH, K. ET AL.: "Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates"</p> <p>PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 3565-3570, XP002078191</p> <p>* whole disclosure *</p> <p style="text-align: center;">-----</p>	1-43

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 September 1998

Date of mailing of the international search report

22. 10. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hermann, R

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/02522

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: **38-43 (all partially)**  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 38-43 (all partially)

Claims 38 and 40-43 are drafted to or refer to undefined analogs, fragments, congeners, variants, muteins, agonists, and antagonists of the mutant enzyme of claim 1.

Claim 39 relates to a mutant kinase, wherein the mutation is completely undefined.

Said claims do not contain the minimal structural and/or functional definitions that are required for an exhaustive and/or meaningful search with reasonable effort. See also the PCT search guidelines C-III 2.1, 2.3, 3.6, 3.7, and C-IV 2.8.

(

(

:

109